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Background.Immunization is one of the most cost effective public health interventions and is 
estimated to have greatly reduced diseases, disabilities, deaths, and inequities worldwide. To 
date, it has allowed totally eradicating one disease and putting more than 7 others under control. 
After testing in clinical trials, only vaccines that meet the requirements of safety and effectiveness 
are registered and authorized by competent authorities to be used in routine and mass 
immunization campaigns. However, it is known that whatever may be the performances, clinical 
phases of a vaccine cannot detect all related adverse events following immunization (AEFIs). This 
is supported by the fact that the sample size of clinical trials is insufficient to detect rare AEFIs; a 
given fraction of AEFIs occurring in the marketed phase of vaccine is related to behavioral and 
biological particularities of vaccinees as they are not rigorously selected as in clinical trials 
patients, others are related to program errors such as non-compliance to vaccines storage or 
administration procedures. Thus, AEFIs may occur following administration of licensed vaccines 
and constitute a risk of damage on the health of patients or a reason for immunization refusal 
since vaccine safety gets more public attention than vaccination effectiveness. 
To anticipate on potentially damaging effects of AEFIs on the health of vaccinees and the 
adherence of population to immunization, it has been recommended that each vaccination 
program develops a vaccine pharmacovigilance system to firstly detect, report, investigate, and 
respond to AEFI and, secondly share information on AEFIs, needed to update the safety profile of 
each licensed vaccine. Currently published studies show that for a number of reasons, vaccines 
pharmacovigilance systems are limited to reach their goals in developing countries such as 
Cameroon. Consequently, several million doses of vaccines are administered to children and 
pregnant women in routine EPI (Expanded Program on Immunization) and to many other specific 
groups in immunization campaigns with little information on vaccines safety generated and made 
available.
The overall goal and specific objectives: This PhDaimed to contribute in securing access to 
immunization by assessing efficient interventions that can be used to improve the 
pharmacovigilance of licensed vaccine. Its activities were embedded in the vaccination campaign 
against meningococcal meningitis A, organized in two health region of Cameroon in 2012, with 
the newly introduced conjugate meningococcal meningitis A vaccine (MenAfrivacTM). The 
objectives of this thesis were i) to investigate the safety profile of the vaccine MenAfrivacTM in the 
mass immunization campaign against meningococcal meningitis organized in Adamaoua and 
North West Health regions of Cameroon; ii) to assess the effect on AEFI reporting, after the 
meningitis vaccination campaign with MenAfrivacTM, of sending a weekly standardized SMS to 
7health workers in charge of AEFI surveillance in health facilities or conducting standardized 
supervision of these personnel using skilled supervisors; and iii) to compare the incidence and 
distribution of MenAfrivacTMAEFIs reported during clinical trial phases to that reported during 
immunization campaigns. 
Method.Three different study designs were used independently to respond to different specific 
objectives of this thesis. The first was a descriptive and analytical study based on data collected 
from AEFIs report forms using a preconceived grid. Passive and stimulated AEFIs surveillance 
were conducted in health facilities and in vaccination sites over a period of two weeks during the 
vaccination campaign and six weeks thereafter. Incidence and types of AEFIs were described by 
time after injection, age group, and health region.The second was an open randomized controlled 
design with three arms. Health facilities that met the inclusion criteria were randomly assigned to 
receive: i) a weekly standardized SMS asking them to report all medical events occurring during 
the intervention period in persons immunized during the campaign, ii) a weekly standardized 
supervisory visit by trained health district focal points for AEFI detection and reporting processes, 
or iii) no intervention besides routine training and sensitization of health facility teams during 
health districts coordination meetings (the control group). The primary outcome was the 
incidence of AEFIs per 100 health facilities per week reported to the Regional Delegation of Public 
Health rate from week 5-8 after the immunization campaign. The third was a systematic review 
conducted to identify all published studies reporting adverse events following MenAfrivac™ 
administration during clinical trials and immunization campaigns. The incidence rate (IR) of 
overall, local, systemic, serious and types of reported AEFIs were estimated and compared 
between clinical trials and immunization campaigns studies using the incidence rate difference 
(IRd). 
Findings.
Safety profile of MenAfrivacTMin immunization campaign 
Of 2’093’381 persons vaccinated in Adamaoua and North West health regions in 2012, 1’352 
AEFIs were reported. Of these, 228 (16.9%) were excluded because they did not meet inclusion 
criteria. Among the remaining 1’124 (83.1%), the incidence rate was 53.7 AEFIs/100’000 doses 
administered/8 weeks. Of 82 serious AEFIs reported, 52 (63.4%) met the case definition. Twenty-
three (28.1%) were investigated, of which 4 (17.4%) were probably related to the vaccination 
(incidence rate: 0.2 AEFIs/100’000 doses administered/8 weeks). Fever was the commonest AEFI 
with 626 cases (incidence rate: 31.4 AEFIs/100’000 doses administered/8 weeks). Proportions of 
subjects with different primary SOC (system organ class) disorders varied by age group, gastro-
8intestinal and respiratory being more frequent in children aged <4 years and neurological and 
general conditions more in adults for example. 
Effects of SMS or supervision on AEFI reporting.
A total of 348 (77.2%) of 451 health facilities were included, and 116 assigned to each of three 
groups. The incidence rate of reported AEFIs per 100 health facility per week was 20.0 (15.9-24.1) 
in the SMS group, 40.2 (34.4-46.0) in supervision group and 13.6 (10.1-16.9) in the control group. 
Supervision led to a significant increase of AEFI reporting rate compared to SMS [adjusted RR=2.1 
(1.6-2.7; p<0.001] and control [RR=2.8(2.1-3.7); p<0.001)] groups. The effect of SMS led to some 
increase in AEFI reporting rate compared to the control group, but the difference was not 
statistically significant [RR =1.4(0.8-1.6); p=0.07)].
Safety profile of MenAfrivacTM in clinical trials and vaccination campaigns
Seven studies were included from 6 publications including 4 clinical trials and 3 immunization 
campaigns. The overall AEFI IR was 4.6 (4.5-4.7) per 100’000 doses administered per week. In 
clinical trials studies, the IR per 100’000 doses administered per week of overall, local, and 
systemic AEFIs were 10’047, 11’499, and 17’248 respectively. In immunization campaigns, these 
values for overall, local, and systemic AEFIs were 4.0, 0.59, and 3.12 respectively. None of 10 
serious AEFIs reported during clinical trials was related to the vaccine. Of 41 serious AEFIs 
reported during immunization campaigns, 5 were probably related to vaccine. IR of AEFIs were 
higher in clinical trials than in immunization campaigns studies, the difference (IRd) for overall 
AEFIs being of 10043 (95% CI 10042-10044) per 100’000 doses per week, for local of 11’498 
(11’498-11’498), for systemic of 17’245 (17’245-17’245)] and for serious AEFIs of 1.55 (1.54-1.56). 
The AEFI IR decreased by more than 99.9% for overall, local, systemic and 99.5% for serious AEFIs 
from clinical trials to immunization campaigns. 
Conclusion 
Neither new safety signal nor increased incidence of serious AEFIs compared to previous mass 
immunization campaign withMenAfrivacTMwas observed. There were age differences in incidence 
and type of AEFIs that are probably related to different background incidence of diseases and 
different susceptibilities or reporting rates in these different age groups.
Supervision was more effective than SMS or routine training in improving AEFI reporting rate. It 
should be part of any AEFI surveillance system. SMS could be useful in improving AEFI reporting 
rates but strategies need to be found to improve its effectiveness, and thus maximize its benefits.
The magnitude of the difference between IR of AEFI as evaluated in the controlled setting of 
clinical trials and more pragmatic approach of mass vaccination campaigns was huge. IR of AEFIs 
was more than 99% lower in vaccination campaigns than in clinical trials, including for the 
9reporting of serious ones. Although the objective of pharmacovigilance is not to identify all minor 
AEFIs, sustainable strategies including for example standardization of hospital registries with 
information on vaccination status to improve active case detection in hospitals to allow better 
reporting and investigation of causality and stimulation of reporting using adequate supervision 
and communication technologies such as SMS reminders need to be put in place. 
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Résumé
Contexte. . La vaccination est l'une des interventions de santé publique les plus efficiente qui 
contribue à la diminution de la morbidité, mortalités et des inégalités dans le monde entier. À ce 
jour, elle a permis d’éliminer une maladie et de contrôler plus de 7 autres. Après avoir été testés 
lors d’essais cliniques, seuls les vaccins qui répondent aux exigences de sécurité et d'efficacité 
sont enregistrés et autorisés par les autorités compétentes pour être utilisés dans les 
programmes de vaccination de routine et lors des campagnes de vaccination. Toutefois, il est 
connu que quelles que soient leurs performances, les phases de développement cliniques d'un 
vaccin ne peuvent pas détecter toutes les manifestations adverses post immunisation (MAPI). 
Ceci s’expliquerait par le fait que la taille d'échantillon des essais cliniques est limitée pour 
détecter les MAPI rares; une fraction donnée de ces MAPI est liée à des particularités 
comportementales et biologiques des personnes vaccinées qui ne sont pas rigoureusement 
sélectionnées comme lors des essais cliniques ; une autre est liée aux erreurs programmatiques 
associées au non-respect des procédures de conservation et d’administration des vaccins. Ainsi, 
des MAPI peuvent survenir après l'administration de vaccins homologués et constituer un risque 
de dommages sur la santé des patients ou une raison de refus de la vaccination, d’autant plus que 
l’attention du public est plus facilement attirée par les problèmes de sécurité des vaccins que par 
leur efficacité.
Pour anticiper sur les effets potentiellement néfastes des MAPI sur la santé des personnes 
vaccinées et l'adhésion de la population à la vaccination, il a été recommandé que chaque 
programme de vaccination développe un système de pharmacovigilance afin d’une part de 
détecter, notifier, investiguer et répondre aux MAPI et d’autre part, rendre disponibles les 
données de la surveillance des MAPI pour la mise à jour du profil de sécurité de chaque vaccin 
homologué. Actuellement les études publiées montrent que, pour un certain nombre de raisons, 
les systèmes de pharmacovigilance ne sont pas très performants, et ne permettent pas de ce fait 
d’atteindre leurs objectifs dans les pays en développement comme le Cameroun. Par conséquent, 
plusieurs millions de doses de vaccins sont administrés aux enfants et aux femmes enceintes dans 
le cadre du PEV (Programme élargi de vaccination) de routine et aux groupes spécifiques variés 
lors des campagnes de vaccination. Très peu d'informations en sont disponibles et accessibles sur 
les MAPI survenues.
Objectifs. Cette thèse a pour objectif d’améliorer la performance du système de 
pharmacovigilance en évaluant l’efficience de nouvelles interventions dans le contexte d’une 
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vaccination de masse. Ses activités ont été intégrées dans la campagne de vaccination contre la 
méningite à méningocoque A, organisée dans deux régions du Cameroun en 2012, avec le vaccin 
conjugué nouvellement introduit contre la méningite à meningocoque A (MenAfriVacTM). Les 
objectifs de cette thèse sont i) d’étudier le profil de sécurité du vaccin MenAfriVac ™ lors de la 
campagne de vaccination de masse contre la méningite à méningocoques A organisée dans les 
régions de l'Adamaoua et du Nord-Ouest du Cameroun  ii) d'évaluer l'effet de l'envoi d'un SMS 
hebdomadaire standardisé aux personnels de santé en charge de la surveillance des MAPI dans 
les formations sanitaires ou de la supervision de ces personnels de santé par des superviseurs 
qualifiés sur la notification des MAPI, après les campagnes de vaccination contre la méningite 
avec MenAfriVac™ ; et iii) de comparer l'incidence et la distribution des  MAPI MenAfriVac™ 
signalées lors des phases d'essais cliniques à celles rapportées lors des campagnes de vaccination.
Méthodologie. Trois différents types d'étude ont été utilisés de façon indépendante pour 
répondre à chacun des trois objectifs spécifiques de cette thèse. Le premier était une étude 
descriptive et analytique basée sur des données recueillies sur les fiches de notification des MAPI 
à l’aide d’une grille préconçue. Une surveillance passive stimulée a été menée dans les formations 
sanitaires et dans les sites de vaccination sur une période de deux semaines au cours de la 
campagne de vaccination et pendant les six semaines qui suivaient la fin de la campagne. Les 
incidences et les types de MAPI ont été décrits en fonction du délai de survenue après 
l'administration des vaccins, du groupe d'âge, et de la région. La deuxième étude était une étude 
randomisée et contrôlée avec trois groupes. Les formations sanitaires qui répondaient aux 
critères d'inclusion ont été assignées au hasard à recevoir: i) un SMS hebdomadaire standardisé 
leur demandant de signaler tous les événements médicaux survenus pendant la période 
d'intervention chez les personnes immunisées durant la campagne, ou ii) une visite de supervision 
hebdomadaire par le point focal surveillance des MAPI du district de santé, ou iii) aucune 
intervention autre que la formation de routine et de sensibilisation au cours des réunions de 
coordination des districts de Santé (groupe de contrôle). Le principal effet mesuré était 
l'incidence des MAPI pour 100 formations de sanitaires par semaine rapportée à la délégation 
régionale de la Santé Publique, de la semaine 5 à la semaine 8 après la campagne de vaccination.
 Le troisième type d’étude était une revue systématique portant sur toutes les études publiées 
dans lesquelles les MAPI survenant après l'administration du MenAfriVac™ au cours des essais 
cliniques et des campagnes de vaccination ont été notifiés. Les taux d'incidences (TI) de 
l'ensemble des MAPI, des MAPI locales, systémiques et graves, ainsi que les types de MAPI 
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notifiées ont été estimés et comparés entre les essais cliniques et les études menées lors des 
campagnes de vaccination à l’aide de la différence de taux d'incidence (IRD).
Résultats.
Sécurité du MenAfriVacTM lors de la campagne de vaccination
Des 2'093'381 personnes vaccinées dans les régions de l'Adamaoua et du Nord-Ouest en 2012, 
1'352 MAPI ont été notifiées. Parmi celles-ci, 228 (16,9%) ont été exclues parce qu'elles ne 
répondaient pas aux critères d'inclusion. Pour les 1'124 (83,1%) restantes, le taux d'incidence des 
MAPI était de 53,7 MAPI/100'000 doses administrées/8 semaines. Des 82 MAPI graves notifiées, 
52 (63,4%) répondaient à la définition de cas. Vingt-trois (28,1%) ont été investiguées, dont 4 
(17,4%) étaient probablement liées à la vaccination (taux d'incidence: 0,2 MAPI/100'000 doses 
administrées/8 semaines). La fièvre était la MAPI notifiées la plus fréquente avec 626 cas (taux 
d'incidence: 31,4 MAPI/100'000 doses administrées/8 semaines). Les proportions de personnes 
présentant un syndrome caractérisant chaque SOC (system organ class) identifié variaient en 
fonction des groupes d'âge. Les affections gastro-intestinales et respiratoires étant les plus 
fréquentes chez les enfants âgés de <4 ans et les troubles neurologiques et généraux plus 
fréquents chez les adultes.
Effets du SMS ou de la supervision sur la notification des MAPI.
348 (77,2%) des 451 formations sanitaires recensées ont été incluses et 116 attribuées à chacun 
des trois groupes. Le taux d'incidence de MAPI signalées pour 100 établissement de santé par 
semaine était de 20,0 (15,9 à 24,1) dans le groupe de SMS, de 40,2 (34,4 à 46,0) dans le groupe de 
supervision et de 13,6 (10,1 à 16,9) dans le groupe contrôle. La supervision a entrainé une 
augmentation significative du taux de notification des MAPI comparativement au groupe 
recevant le SMS [RR ajusté = 2,1 (1,6 -2.7; p <0,001] et au groupe contrôle [RR = 2,8 (2.1-3.7); p 
<0,001)]. L'envoi des SMS entraîne une certaine augmentation des taux de notification des MAPI 
par rapport au groupe de contrôle, mais la différence n'a pas été statistiquement significative [RR 
= 1,4 (1.0-1,9); p = 0,51)].
Sécurité de MenAfrivacTM lors des essais cliniques et des campagnes de vaccination
Sept études ont été incluses à partir de 6 publications dont 4 essais cliniques et 3 études menées 
lors des campagnes de vaccination. Le taux d’incidence global des MAPI était de 4,6 (4,5-4,7) par 
100'000 doses administrées par semaine. Dans les essais cliniques, les TI par 100'000 doses 
administrées par semaine de MAPI globales, locales et systémiques étaient de 10'047, 11'499 et 
17'248 respectivement. Lors des campagnes de vaccination, ces valeurs pour les MAPI globales, 
locales et systémiques étaient de 4,0 ;   0,59 et 3,12 respectivement. Aucunes des 10 MAPI graves 
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notifiées lors des essais cliniques n’était liée au vaccin. Des 41 MAPI graves notifiées lors des 
campagnes de vaccination, 5 étaient probablement liées au vaccin. Le TI des MAPI étaient plus 
élevés lors des essais cliniques que lors des campagnes de vaccination, la différence des TI 
concernant les MAPI global étant de 10’043 (IC à 95%= 10’042-10’044) pour 100'000 doses par 
semaine, de 11'498 (11'498-11'498), 17'245 (17'245-17'245)] et 1,55 (1,54 à 1,56) pour les MAPI 
locales, systémiques et graves respectivement. Le TI des MAPI a diminué de plus de 99,9% en ce 
qui concerne les MAPI globale, locales, systémiques et de 99,5% pour les MAPI graves, quand on 
passe des essais cliniques aux études menées lors des campagnes de vaccination.
Conclusion.Aucune augmentation de l'incidence des MAPI graves n’a été observée 
comparativement aux précédentes campagnes de vaccination de masse avec le MenAfriVac™. Il y 
avait des différences d’incidence et de type da MAPI selon l'âge, différences probablement liées à 
des différences d’incidences des maladies et des sensibilités ou des différences de taux de 
notification parmi les différents groupes d’âge.
La supervision a été plus efficace que le SMS ou la surveillance de routine sur l'amélioration du 
taux de notification des MAPI. Elle devrait faire partie de tout système de surveillance des MAPI. 
Le SMS pourrait être utile pour améliorer les taux de notification des MAPI mais les stratégies 
doivent être trouvées pour améliorer son efficacité, et donc maximiser ses avantages.
L'ampleur de la différence entre les TI des MAPI dans le cadre d'essais cliniques et lors des 
approches plus pragmatiques des campagnes de vaccination de masse était considérable. Le TI de 
MAPI était de plus de 99% inférieur lors des campagnes de vaccinations par rapport aux essais 
cliniques, y compris le taux de notification des MAPI graves. Bien que l'objectif de la 
pharmacovigilance n’est pas d’identifier toutes les MAPI mineures, des stratégies pérennes, telles 
que la standardisation des registres des formations sanitaires incluant au moins une variable sur 
les antécédents de vaccination par exemple pourrait améliorer la détection active des cas dans les 
formations sanitaires et permettre une meilleure notification et l’investigation des cas de MAPI; 
la stimulation de la notification en utilisant la supervision et les technologies de communication 
telles que des rappels par SMS devraient être mis en place.
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Zusammenfassung
Kontext.Impfungen gehören zu den effizientensten Public Health Interventionen und trugen in 
grossem Ausmass weltweit dazu bei, Krankheiten, Behinderungen, Todesfälle sowie auch 
Ungerechtigkeiten zu reduzieren. Bis heute konnte eine Krankheit total ausgerottet werden, und 
mehr als sieben weitere sind unter Kontrolle. Einzig Impfstoffe, welche die Bestimmungen 
betreffend Sicherheit und Wirksamkeit in klinischen Versuchen unter Beweis stellen konnten, 
erhalten die Bewilligung der kompetenten Behörden, in Routineprogrammen oder 
Massenimpfkampagnen angewendet zu werden. Wir wissen aber auch, dass trotz 
nachgewiesener Leistung diese klinischen Versuche nicht alle mit der Impfung im Zusammenhang 
stehenden unerwünschten Nebenwirkungen (AEFIs - Adverse Events Following Immunization) 
entdecken können. Dies erklärt sich aus der Tatsache, dass die Stichproben dieser klinischen 
Versuche oft zu klein sind, um seltene AEFIs zu entdecken. Dazu kommt, dass ein gewisser Anteil 
der AEFIs, welche in der Vermarktungsphase der Impfstoffe auftreten, im Zusammenhang mit 
Besonderheiten im Verhalten und in biologischen Faktoren der geimpften Personen stehen, da 
diese eben nicht gleichermassen sorgfältig wie in klinischen Studien ausgewählt werden. Andere 
AEFIs wiederum werden durch Fehler im Impfprogramm hervorgerufen, wie zum Beispiel das 
Nichtbeachten der idealen Lagerungsbedingungen oder gar bei der Verabreichung der 
Impfungen. Deswegen können AEFIs auch bei registrierten Impfstoffen auftreten und bergen 
stets ein gewisses Risiko für die Gesundheit der Patienten. Sie werden auch als Gründe der 
Ablehnung eines gewissen Impfstoffes in den Vordergrund gestellt, da in der Bevölkerung der 
Sicherheit von Impfstoffen manchmal eine grössere Beachtung geschenkt wird wie der 
Wirksamkeit des Produktes. Um nun solchen potentiell für die Gesundheit der Geimpften 
schädigenden Effekte vorzubeugen, und um damit auch eine bessere Compliance einer 
gegebenen Bevölkerung zu erreichen, wurde empfohlen, dass jedes Impfprogramm ein 
Meldesystem entwickelt mit den Zielen, einerseits AEFIs früh zu entdecken, zu registrieren, zu 
untersuchen und zu beheben und andrerseits die AEFIs Information zu verarbeiten, damit das 
Sicherheitsprofil eines jeden lizensierten Impfstoffes angepasst werden kann. Publizierte Studien 
zeigen, dass die Impfmeldesysteme von Entwicklungsländern wie Kamerun die gesteckten Ziele 
aus verschiedenen Gründen nicht ganz erreichen. Folglich werden in den Routine 
Impfprogrammen (EPI – Expanded Program on Immunization) mehrere Millionen Impfdosen an 
Kinder, schwangere Frauen und viele andere spezifische Gruppen verabreicht ohne dass die 
Sicherheit weiter untersucht wird und die Resultate dann auch zugänglich sind. 
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Diese PhD Forschung beabsichtigt, zu vermehrter Sicherheit im Zugang zu Impfstoffen 
beizutragen, indem sie mehrere effiziente Interventionen kritisch betrachtet, welche zu einer 
Verbesserung des Meldesystems von bereits zugelassenen Impfstoffen geeignet wären. Ihr Blick 
richtet sich vorwiegend auf die Meningokokken-Meningitis A Schutzimpfung, welche in zwei 
Regionen von Kamerun im 2012 eingeführt wurde. Es handelt sich um den neu eingeführten 
Meningokokken Meningitis A Impfstoff mit dem Namen MenAfrivacTM. Die Ziele dieser 
Doktorarbeit sind i) das Sicherheitsprofil von MenAfrivacTM in Massenimpfkampagnen gegen 
Meningitis zu untersuchen, welche in den beiden kamerunesischen Gesundheits-Regionen 
Adamaoua und Nord-West organisiert wurden und ii) dabei die Wirksamkeit des AEFI 
Meldesystems zu evaluieren, bei welchem nach der Impfung mit MenAfrivacTM entweder 
wöchentlich standardisierte SMS an das mit dem AEFI Meldesystem betraute 
Gesundheitspersonal in den verschiedenen Gesundheitszentren versandt wurden oder aber eine 
standardisierte Supervision derselben durch ausgebildete Fachleute vor Ort durchgeführt wurde 
und schliesslich iii) die Inzidenz und Verteilung der MenAfrivacTM AEFIs der Impfkampagnen mit 
jenen der publizierten Daten aus den klinischen Feldversuchen zu vergleichen.
Methode.In dieser Forschung fanden je nach den verschiedenen spezifischen Zielsetzungen und 
unabhängig voneinander, drei verschiedene Studien-Designs Anwendung.Das erste war eine 
deskriptiv analytische Studie, welche sich auf Daten berief, welche aus den vorgegebenen 
Formularen des AEFI Meldesystem konstituierte. Dabei handelte es sich um ein passives- aber 
auch um ein aktiv gefördertes AEFI Meldesystem, welches in den Gesundheitszentren und 
anderen Orten, wo Impfungen durchführt wurden, über einen Zeitraum von zwei Wochen 
während der Impfkampagnen und bis sechs Wochen danach funktionierte. Die Inzidenz und 
Typologie der AEFI wurden beschrieben nach dem Zeitpunkt deren Auftretens nach der Impfung, 
nach Altersgruppe der betroffenen Person und nach der Gesundheitsregion, wo die AEFI 
auftraten. Das zweite Design war eine offene randomisierte Studie mit drei Gruppen. Jene 
Gesundheitszentren, welche die Einschlusskriterien erfüllten wurden zufällig zugeordnet, um i) 
wöchentlich standardisierte SMS zu erhalten, welche danach fragten, alle während der 
Impfkampagne an geimpften Personen beobachteten medizinischen Ereignisse zu melden, oder 
ii) eine wöchentliche, standardisierte Supervision mit speziell zur Erkennung und Meldung von 
AEFIs ausgebildetem Fachpersonal zu erhalten oder aber dann iii) von gar keiner spezifischen 
Intervention berücksichtigt wurden ausser der routinemässig durchgeführten Ausbildung und 
Sensibilisierung der Teams im Gesundheitszentrum anlässlich von Distrikt-Koordinations-
Sitzungen (dies war die Kontroll-Gruppe). Der Primary Outcome war die AEFI Inzidenz pro 100 
Gesundheitszentren pro Woche, welche an die Regionale Public Health Delegation zwischen 
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Woche 5 bis 8 nach der Impfkampagne gemeldet wurden. Das dritte Design war eine Systematic 
Review, welche alle publizierten Studien über gemeldete AEFI identifizierte, die im 
Zusammenhang mit den klinischen Studien zu MenAfrivacTM und den Impfkampagnen 
durchgeführt wurden. Dabei wurde dann die Inzidenzrate (IR) aller, der lokalen, systemischen, 
und als schwerwiegend geltenden AEFI und deren Natur hochgerechnet und diese von klinischen 
Studien mit jenen der Impfkampagnen verglichen, was dann die Inzidenzraten-Differenz ergab 
(IRD). 
Resultate.
Sicherheitsprofil von MenAfrivacTM in Impfkampagnen 
Im Jahre 2012 wurden von den in den Gesundheitsregionen Adamaoua und Nord-West geimpften 
2’093’381 Personen insgesamt 1’352 AEFIs gemeldet.Anschliessend mussten 228 (16.9%) wegen 
Nichterfüllens der Enschlusskriterien ausgeschlossen werden. Unter den Verbliebenen 1’124 
(83.1%) AEFIs errechnet sich somit eine Inzidenzrate von 53.7 AEFIs/100’000 verabreichten 
Impfungen/8 Wochen.Von den 82 sogenannt schwerwiegend gemeldeten AEFIs, erfüllten 52 
(63.4%) die erforderliche Definition. Dreiundzwanzig (28.1%) wurden untersucht, und 4 (17.4%) 
davon standen wahrscheinlich in einem Zusammenhang mit der Impfung (Inzidenzrate: 0.2 
AEFIs/100’000 applizierten Impfungen /8 Wochen). Fieber war der häufigste AEFI mit 626 Fällen 
(Inzidenzrate: 31.4 AEFIs/100’000 applizierten Impfungen /8 Wochen). Die Anteile von Personen, 
welche von verschiedenen primären Organsystem Störungen betroffen waren, variierten nach 
Altersgruppe. Gastrointestinale- und den Atemapparat betreffende Störungen wurden zum 
Beispiel häufiger bei Kindern unter 4 Jahren und neurologische und allgemeine Erscheinungen 
häufiger bei Erwachsenen beobachtet. 
Auswirkung auf die AEFI Melderate durch SMS Stimulation verglichen mit direkter Supervision 
Insgesamt wurden 348 (77.2%) der 451 Gesundheitszentrern eingeschlossen und je 116 zu je 
einer Gruppe zugeordnet. Die Inzidenzrate der gemeldeten AEFI Fälle per 100 
Gesundheitszentren pro Woche war20.0 (15.9-24.1) in der SMS Gruppe, 40.2 (34.4-46.0) in der 
Gruppe mit direkter Supervision und 13.6 (10.1-16.9) in der Kontrollgruppe. Die Supervision 
führte zu einem signifikanten Anstieg der gemeldeten AEFI Fälle verglichen mit der SMS Gruppe 
[bereinigtes RR=2.1 (1.6-2.7; p<0.001] oder der Kontrollgruppe [RR=2.8(2.1-3.7); p<0.001)]. Die 
SMS Stimulation führte zu einem gewissen Anstieg der gemeldeten AEFI Fälle verglichen mit der 
Kontrollgruppe, aber der Unterschied fiel statistisch nicht signifikant aus [RR =1.4(0.8-1.6); 
p=0.07)].
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Sicherheitsprofil von MenAfrivacTM in klinischen Studien und Impfkampagnen 
Es wurden 7 Beobachtungen eingeschlossen, welche in 6 Publikationen beschrieben wurden – 4 
klinische Versuche und 3 Impfkampagnen.Insgesamt beobachtete man einen AEFI IR von 4.6 (4.5-
4.7) pro 100’000 applizierten Impfungen pro Woche.Studien zu klinischen Versuchen 
rapportierten eine IR pro 100‘000 applizierten Impfungen pro Woche betreffend aller, der lokalen 
und der systemischen AEFIs von 10’047, 11’499, und 17’248 beziehungsweise. In den 
Impfkampagnen waren die Werte betreffend aller, der lokalen und der systemischen AEFIs 4.0, 
0.59, and 3.12 beziehungsweise. Kein einziger der in den klinischen Versuchen als schwerwiegend 
gemeldeten Fälle konnte der Impfung zugeordnet werden. Von den 41 als schwerwiegend 
gemeldeten AEFIs, welche im Laufe von Impfkampagnen auftraten, wurden 5 als wahrscheinlich 
im Zusammenhang mit der Impfung gebracht. Die IR von AEFIs waren höher in den klinischen 
Studien als in den Impfkampagnen. Somit ist die Differenz (IRD) für alle AEFIs 10’043 (95% CI 
10’042-10’044) pro 100’000 verabreichten Impfungen pro Woche, für lokale 11’498 (11’498-
11’498), für systemische 17’245 (17’245-17’245) und für als schwerwiegend geltende AEFIs 1.55 
(1.54-1.56). Die AEFI IR verringerte sich somit um mehr als 99.9% für alle, die lokalen und die 
systemischen AEFIs und um 99.5% betreffend die als schwerwiegend geltende AEFIs ausgehend 
von den klinischen Versuchen zu den Impfkampagnen. 
Vergleicht man mit vorhergehenden Massenimpfkampagnen von MenAfrivacTM, so wurden weder 
neue Sicherheitssignale noch eine erhöhte Inzidenz von als schwerwiegend geltendnen AEFIs 
verzeichnet. Es bestehen altersabhängige Unterschiede im Auftreten und der Art der AEFIs, 
welche wahrscheinlich vor dem Hintergrund einer verschiedenen Inzidenz von Krankheiten und 
verschiedenen Anfälligkeitsprofilen oder auch unterschiedlichen Melderaten für diese 
verschiedenen Altersgruppen zu sehen sind. Die direkte Supervision ist wirksamer als SMS 
Stimulation oder ein Routine Training Kurs bezüglich der Verbesserung der Melderate von AEFIs. 
Die Supervision sollte somit Teil eines jeden AEFI Meldesystems werden. Die SMS sind eventuell 
nützlich bei der Verbesserung der Melderate von AEFIs. Es braucht jedoch neue Strategien, um 
die Wirkung zu erhöhen und so den Nutzen zu maximieren. 
Die Grösse der Differenz zwischen der AEFI IR, wie sie einerseits in kontrollierten Settings der 
klinischen Studien und andrerseits mit einem mehr pragmatischen Ansatz der 
Massenimpfkampagnen evaluiert wurde, war enorm. Die AEFI IR der Massenimpfkampagnen war 
mehr als 99% niedriger als jene der klinischen Versuche, einschliesslich der Meldungne von als 
schwerwiegend geltenden AEFIs. Obwohl die Pharmakovigilanz nicht primär alle leichten AEFIs zu 
identifizieren sucht, braucht es eine Entwicklung nachhaltiger Strategien wie zum Beispiel eine 
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Standardisierung von Spitalregistern, welche die Information des Impfstatus beinhalten, damit 
eine aktive Erkennung der Fälle in den Spitälern mit darauf folgender Untersuchung einer 
eventuellen Kausalität möglich wird. Die Förderung der Melderate durch angepasste Supervision 
und Integration von Kommunikationstechnologie wie SMS muss ausgebaut und fortgesetzt 
werden.
1Chapter 1: Introduction
Effectiveness of immunization as a public health intervention
Vaccination is an intervention that has been proven efficient in preventing child mortality 
worldwide. It is estimated that it saves every year at least 6 million deaths, 400 million life years and 
97 million disability adjusted life years and has helped to control many diseases (1). Compared to 
other public health interventions, it is among interventions with lowest investment risk in human per 
capita development with proven economic impact (1).
Vaccines development and safety assessment
Eachvaccineis developed in threephases including thepreclinical, clinical, and post registration 
phases,in which itssafety, reactogenicity and efficacyare evaluated(2). International and national 
guidelinesfor the regulation ofclinical trials(3; 4) present recommendationsfor safety assessment 
during vaccines clinical development, registration and prequalification phases(5; 
6).Recommendations to ensure the quality and safety of the vaccine when it is marketed are also 
presented in appropriate guidelines(7; 8; 9). 
Importance of post registration AEFI surveillance
Vaccines used in the Expanded Programme on Immunization (EPI) are generally prequalified by WHO 
following a rigorous and standardized procedures (5).What so evertheprequalificationprocedure, 
itmust be knownthat exposureto the vaccinecan induce,beside expected effects, adverse events 
(AE). 
The assessment of drug safety inclinical trials is limited to detect all potential adverse events 
following immunization (AEFIs). Reasons behind these limitations include: i) the non-implementation 
of the standardization of the monitoring andreporting ofAEFIsin clinical trials (10; 11); ii) a given 
fractionofAEFIthat occurin vaccine post registration phase arerelated to patients behavioral, 
biological differencesof targeted populations, failure to comply to contra-indications, vaccine 
storage, transportation, administration and may not be detectedby clinicaltrials; iii) sample sizesof 
clinical trials often lackthenecessarypower to detectrare AEFI(12). It is thus essential that national 
monitoring and reporting systems for vaccine safety be planned as part of immunization 
programmes and/or of pharmacovigilance systems, be efficiently and adequately supplied with 
needed minimum resources, implemented and coordinated. 
A minority of persons who are vaccinated may experience AEFIs that are related to the vaccine, most 
of which are mild and time-limited but can also, in rare cases be serious. The update onthese 
2categories of AEFI isnecessaryto guidedecisions andplans of National regulatory authorities (NRA), 
EPIofficials, policy makers and the pharmaceutical industry.
Whether relatedto the vaccineor not,AEFIscanhandicap theadhesion of the populationto 
vaccination(15; 16).This mustbe preventedsothat vaccinationcontinues to playits role indisease 
control.
Postregistration AEFIsurveillanceis thus essential and recommended to countries implementing 
routine EPI and supplementary immunization activities EPI(17; 18).It allows the updating of 
information on vaccinesafety profile. This informationbeing essentialto those involvedfor the 
continuous improvement ofservice delivery in terms ofvaccination andto ensure theinterest and 
demandof the populationfor vaccination.
AEFI case definition
An AEFI is any untoward medical occurrence which follows immunization and which does not 
necessarily have a causal relationship with the usage of the vaccine (9). The adverse event may be 
any unfavorable or unintended sign, symptom or disease, or abnormal laboratory finding. It can be 
serious or mild. A serious AEFI is a reaction that results in death, hospitalization or prolongation of 
hospitalization, permanent or significant disability, causes congenital abnormality or requires 
intervention to prevent damage or impairment (9). A cluster of AEFIs is two or more cases of the 
same adverse event related in time,place or vaccine administered. Following AEFIs are 
recommended eligible for investigation: serious AEFI;cluster AEFI;suspected signal; suspected 
immunization error;it appears on the list of events defined for AEFI investigation or; it causes 
significant parental or public concern.The ultimate goal of an investigation is to determine whether 
the vaccine or immunization process is responsible for the reported event(s) or to find another cause 
and correct it if possible, and reassure the public. There are 5 possible causes of AEFI (9). These 
include: i) vaccine product-related reaction: an AEFI that is caused or precipitated by a vaccine due 
to one or more of the inherent properties of the vaccine product; ii) vaccine quality defect-related 
reaction: an AEFI that is caused or precipitated by a vaccine that is due to one or more quality 
defects of the vaccine product, including its administration device as provided by the manufacturer; 
iii) immunization error-related reaction (formerly “programme error”): an AEFI that is caused by 
inappropriate vaccine handling, prescribing or administration and thus by its nature is preventable; 
iv) immunization anxiety-related reaction: an AEFI arising from anxiety about the immunization; v) 
coincidental event: an AEFI that is caused by something other than the vaccine product. Cluster of 
AEFIs are usually due to immunization error-related reactions. To promote comparability of reported 
AEFI, cases definition and clinical classification of cases should be done following the Brighton 
3Collaboration and The Medical Dictionary for Regulatory Activities terminology (MedDRA) 
respectively (74, 77). 
Goal of AEFI surveillance
Immunization safety surveillance aims at early detecting, reporting, investigation and appropriately 
responding to adverse events in order to lessen the negative impact on the health of the individuals 
and on the immunization programme. Appropriate vaccine surveillance is an indicator of 
immunization programme quality (9). It also enhances programme credibility and can provide actual 
country data on vaccine risks. In Cameroon, all AEFI are recommended to be detected at health 
facilities and reported to the EPI through the health district service and regional delegation of public 
health and then to Department of Pharmacy, Drugs and Laboratory (80). During campaigns, all AEFI 
are recommended to be detected at vaccination sites and health facilities and reported to the EPI 
through the health district service and regional delegation of public health and then to experts 
committee in charge of AEFIs monitoring. 
Activities for better immunization safety at global level
Since 1999,vaccine safetyhas been identifiedas a priority projectby the World Health Organization 
(WHO)(19).Aproject aiming to improve the global vaccine safety was launched andfocused on: 
insuring vaccine safety from clinical trials up to point of use; conducting research and development 
to insure safer and simpler delivery systems; improving access to safer and more efficient systems 
for vaccine delivery and sharps waste management; and identifying and managing risks related to 
immunization. One of the main supporting activitiesimplementedby WHO forthe latter was the 
establishment of a Global Advisory Committee on Vaccine Safety (GACVS) to provide support needed 
to improve AEFI surveillance in countries (20; 21).In theseperspectives,a number ofactionshave 
already beentakenincluding the productionand provisionofguidelines onsetting up and running a 
vaccinepharmacovigilance system and implementing its activities(18; 22; 23).Also, to contribute in 
establishing effective vaccine pharmacovigilance systems in all countries, the WHO is developing a 
global vaccine safety blueprint (24). Preliminary activities of this initiative included identifying local 
experience, available infrastructures, needs and priorities of vaccine safety monitoring expressed in 
Low- and Middle-Income Countries (LMIC) (25). 
Developing AEFI surveillance system at country level
Thebasic elementsforthe establishmentof AEFIs surveillance and management ofpharmacovigilance 
centersin generalhave been described ininternational guidelines(28).These guidelinesdetail the AEFIs 
surveillance objectives, the minimum informationexpected in an AEFI reporting form, thedetection, 
reporting investigatingand data analysis procedures, and the required mechanisms for collaboration 
4and coordinationactivities among institutions involved. The minimum needed equipment,human 
resourcesand activitiesare also described. It underlines that the choiceof the local institutions tohost 
thepharmacovigilanceand AEFI surveillance servicesis crucial for the success of its activities. A recent 
survey of vaccine safety stakeholders with different professional backgrounds in LMIC identified 
following as actions to be implemented to improve existing vaccine safety systems in LMIC:improve 
the quality of existing vaccine safety data, to enhance local analytic capacity, to establish health-care 
databases and to enhance information sharing within and across countries (25). 
Challenges of AEFI surveillance in vaccine clinical trials
The detection, reporting and investigation ofAEFI as well as results presentation on vaccine safety 
during clinical trials are notalways done as recommendedin guidelines (3).A review published in 
2005 underlined number of weaknesses: methods of many clinical trials lacked information on AEFIs 
case definition, procedures of AEFI detection, reporting, investigation, duration and periodicity of 
AEFI follow up.Inconsistency between presented results and described methodology and lack of 
standardization of AEFI surveillance procedures among clinical trials were other weaknesses pointed 
out (29). About half of articles reporting clinical trials failed to disclose result on drug safety. 
Anotherreview on clinical trials conducted in developing countries and publishedin 2012underlined 
the need to harmonize safety reporting procedures and to implement standardized AEFIs case 
definitions (31).The above mentionedchallenges need to be addressed in order to ensure the 
reliabilityof informationonvaccine safetypresentedin clinical trial reports.Italsounderlines the 
importantroleto be playedbyvaccines post licensure pharmacovigilance in the monitoringof 
vaccinesafety profile.
Challenges of AEFIs surveillance in routine and immunization
The establishmentand the functioningof a credible vaccine pharmacovigilance system are essential 
forthe monitoring of the safety profileof vaccinesused inthe EPIand supplementaryimmunization 
activities (SIAs)(18). But thecurrent landscape ofnational pharmacovigilance systemsdoes not meet 
yetexpectations.Published studies conducted in 55 LMIC countries highlighted number of 
challenges:halfof the countries donot yethavea pharmacovigilance systemin place;only about 45% of 
these countries have trained human resources andbudget allocated for pharmacovigilance (32); till 
as recently as in 2005, there were stillcountries whereimmunization activitieswere carried out 
withoutany plan to conduct AEFI surveillanceand countries where initiatives aimed at the 
standardization of AEFI case definitions were unknown (33).In a numberof countries, remarkable 
progresses arenoted. As the example of Burkina Faso where basic structures for 
5pharmacovigilanceand AEFI surveillance activities have been established but the system still 
lacksregulation andspecificguidelines for adequateorganization andcoordination of activities(34). 
At health facilities level, AEFI underreportinghas been identified as one ofmajorweakness(35; 36; 37; 
38).
Asurvey recently conductedbyWHOidentifiedtheperceivedand documented needs to address in 
order to improve vaccine safety systems in countries(25).
Challenges of AEFI surveillance in immunization campaigns
Mass vaccination campaignsare organized eitherto prevent an epidemic, in responseto an epidemic, 
or to improve the coverage ofroutine EPI.For over 10yearsat least 5campaigns are organized in 
Cameroun yearly targeting ina very few daysa large number ofpeople.Tovaccinatea largenumber of 
people,health personalunaccustomedto vaccinationare solicited to complement tosupplement 
regular EPI staff. Thus, immunization campaignsinvolve inexperienced staffinimmunization activities, 
thelarge number of doses given over a short period of time leading to many occurring AEFIs 
including coincidental events (23).Immunization activitiesare oftenconducted inoutreach, mobile, or 
door to door strategies andlimit the possibilitiesto maintain thecoldchain.This situation is known to 
predispose to an increased incidence of program errors.In addition, it is fertile grounds for rapid 
expansion ofrumors that can lead torefusalor decreasedadhesionof the populationsto 
vaccination(23).
Underreporting and described related factors
Several studies havedescribedfactors associated withpoor performancesof pharmacovigilancein 
generalandAEFIsreporting in particular.Thesefactors may act either at the level ofimmunization 
programs,health facilitiesor the community.
At immunization program level, factors influencing AEFI reporting arepoorly described. Thereporting 
ratemay depend on theavailability ofguidelines and procedures, resources, surveillance design, 
frequency and qualityoftraining and supervisionimplementedin the framework of AEFI 
monitoring(39; 40; 41). 
At health facilities level, the main determinants of underreporting are related to service delivery and 
particularly to health care staff. Work overload, privileged professional categories (physician); 
ignorance, fear of being accused of ignorance, beliefs and perceptions, doubt on the case definition 
and period of surveillance, lack of interest and indifference resulting from inadequate training have 
been identified as main determinantsassociated with underreporting (15; 42; 43; 44). We did not 
find studies describing the relationship betweenthe availability of regulations, resources, guidelines, 
standard operating procedures, reporting forms, incentives and adverse events reporting rates.
6At community level, limited knowledge, awareness and perceptions of persons vaccinated have 
beenidentified as factors influencing the AEFI reporting rates (45; 46; 47). The geographical and 
financial accessibility of health facilities to communities, and communities’ perceptions regarding 
service delivery in health facilities can be other factors influencing AEFI reporting.
The main consequence of underreporting is that a considerable proportion of serious adverse 
events, program errors and AEFIs that cause concern to the public are not detected and 
investigated.
Interventions to improve AEFI surveillance
To the best of our knowledge no intervention hasyet been tested or implemented to assess effects 
of improvingthe regulation,resources, guidelines or equipment on rate and/or quality AEFI 
reported.The direct impact ofthe international initiativeslike Programme for International Drug 
Monitoring (PIDM)andGlobal vaccine safety blueprint have not yet been assessed(48; 26).
At the operational level interventions have been mainly targeting patients but not health facilities. 
The most tested intervention has been the use of short message service (SMS) tostimulate AEFI 
reporting. (50; 51; 52). This strategy has been shown effective in improving AEFIsdetection and 
reporting rates (53).
Many other alternatives have been assessed (55; 56; 57). These included among other the use of 
phones, fax, worldwide web or e-mail reporting. These channels have been limited as they require 
adequate equipment, internet network coverage and permanent power supply.Training has been 
proven to improve the AE reporting but this has been limited to certain category of health personnel
 Supervision has been proven, during masses immunization campaigns organized in Cameroon, to 
contribute in improving AEFIs reporting rate and the completeness of reporting forms (56).But this 
result could not be generalized since there was not appropriate control intervention and the 
supervision procedure was not rigorously standardized in different sites. 
Supervision has various definitions and ways of implementation.In health domain, it includes more 
qualified health personnel interacting with generally less qualified ones to verify and insure that 
their tasks and activities are implemented following predefined guidelines (57). It is part of the 
district health system like in Cameroon. In this country, basic health care is often provided by nurses 
and in some case general practitioners in Integrated Health Centers under the supervision of the 
health district staff. The health district staffs are supervised from the regional staff which is also 
supervised by the ministerial staff. Supervision is part of clinical practice activities and health 
programmes but is not implemented in all health facilities and programs because of lack of human 
7and financial resources and of poor planning. Health programs like EPI implement it more rigorously 
and regularly. 
A review of nine controlled studies comparing supervision versus no supervision showed a significant 
positive effect in two out of three studies; enhanced supervision significantly improved health 
worker performances in two out of five studies. In one study, there was no effect of decreasing 
supervision frequency on service utilization (54). In this review, types of procedures and 
implementation of supervision, study sites, study power, targeted population and activities as well 
as outcome type and assessment were very diverse.
Communicating via mobile phone using Short Message System (SMS) is a cheap mean of 
communication. It can be used to strengthen the health system by speeding the exchange of 
information between health facilities and health structures.The WHO is promoting the use of new 
technologies including SMS as strategy to improve health delivery in resource-limited settings 
(58).The effect of this policy is taking ground in Cameroon with mobile telephones and free 
communication offered by WHO to all health facilities involved in surveillance activities since 
December 2013.Since then, SMS is being used to stimulate AEFI reporting but its benefits are still 
limited since it is neither systematic nor generalized.There arealsoattempts to useSMSfor cases 
reporting but initiativesin this direction arestill isolated.In other setting, it has been demonstrated to 
significantly improve the mobilization of anesthesia personnel in response to mass casualty 
incidentswith some limitations though (59). A portionof persons targeted by SMS targetsdid not read 
it intimeandeveryone readingthe message did notreactin time. The present study offers an 
opportunity to test efficacy of SMS compared to that of supervision over routine AEFI monitoring 
practiceson AEFI reportingamong health workers during a vaccination campaign against 
meningococcal meningitis A using the vaccine MenAfrivacTM. 
The burden of meningitis in Africa
Infectious meningitis can be viral, fungal, parasitic or bacterial but Neisseria meningitidis is the 
predominant cause of bacterial meningitis epidemic and is the most frequent worldwide. For over 
100 years, the disease has affected all continents. The strains associated with outbreaks include: A, 
B, C, and W135 and X (60). The meningitis A strain is the most common, morbid and rife in twenty-
twoSahelian Africa countries (from Senegal to Ethiopia) called meningitis belt of Africa with the 
population at risk estimated at over 400 million. Outbreaks typically occur in the dry season with an 
estimated annual incidence of 1000-1200 cases per 100,000 habitants per epidemic (60). The 
baseline incidence varies between 10-20 cases per 100 000 habitants. In the period 1993-2012, close 
to one million cases occurred causing about 100,000 deaths. Treatmentcostsare aboveincome of 
8severalaffected families andconstitutean obstacle to development (61). From the time 
MenAfrivacTMhas been used in immunization campaigns to prevent the disease, the incidence and 
specific mortality related to Meningococcal meningitis A have been rapidly decreasing (63). 
Cameroon is one of the countries affected by the disease.Table 1, presents the number of cases of 
Meningococcal meningitis and deaths reported in Cameroon from 2009 to 2012. We have to 
underline that low proportion of cases and deaths are reported due to poor performances of the 
epidemiological surveillance. 
Table I: Number of cases of Meningococcal meningitis and deaths reported in Cameroon from 
2009 to 2012 (source: department of disease control, Cameroon Ministry of Public Health).
Year Case Deaths Lethality 
2009 1001 122 12,2%
2010 835 71 8,5%
2011 2733 191 7%
2012 671 74 11%
The Meningitis Vaccine Project (MVP)
Meningitis epidemics raging in Africa for a long time could not be controlled in spite of reactive mass 
vaccination of the population at risk with meningococcal polysaccharide (PS) vaccines (64). The 
efficiency of this vaccine was indeed hampered because of its limited efficacy in infants and young 
children.Also, it did not decrease carriage, neither conferred herd immunity (64).Inspired by 
successful experiences of conjugate vaccines against Haemophilus B and Meningococcal meningitis C 
(67), the WHO called in 2000, for a group of experts to assess the feasibility ofdeveloping an 
affordable meningococcal A or A/C conjugate vaccine to control meningitis as public health problem 
in Africa (66). After assessment, the group reached the conclusion that this project was feasible.An 
initiative involving the partnership between WHO and Program for Appropriate Technology in Health 
(PATH), funded by the Bill and Melinda Gates Foundation,with supports ofdelegations of African 
ministries of health and a group of international experts called Meningitis Vaccine Project (MVP) was 
thus born with the aim to develop, test, and license MeningococcalMeningitis A Conjugate vaccines 
for Sub-Saharan Africa. The meningococcal meningitis Aconjugate vaccine (MenAfrivacTM) was then 
developed by the Serum Institute of India LTD (64).Clinical phases began in 2005 and were 
implemented in India and Africa. At the end of these phases, the vaccine was proven effective and 
safe and marketed in India in 2009 (66). It was then introduced in Burkina Faso in 2010 (68). Till 
2012, over 100 million persons have been vaccinated during mass preventive vaccination campaigns 
9in 10 countries with this vaccine (66). The epidemiological surveillance following these campaigns 
has not reported a case of meningitis A detected in a vaccinated person. The incidence and specific 
mortality of meningococcal meningitis Aare therefore considerably decreasing but outbreaks of 
meningococcalmeningitis W135are still persisting (60). From AEFI surveillance, there is no reason for 
concern regarding the safety of the vaccines (38). 
Description ofMenAfrivacTM
MenAfrivacTM (Meningococcal A Conjugate vaccine) is a lyophilized vaccine made of purified 
meningococcal A polysaccharide covalently bound to tetanus toxoid (TT), which acts as a carrier 
protein. The vaccine consists of purified group-specific bacterial polysaccharide from Neisseria 
meningitidis group A (72). It satisfies the WHO recommendations to assure vaccine quality, safety 
and efficacy (73). It is indicated for active immunization against invasive meningococcal disease 
caused by Neisseria meningitidis group A. It does not protect against other forms of invasive disease 
caused by other meningococcal groups (such as Groups B, C, W135, and Y). 
MenAfrivacTM has shown adverse reactions during clinical trials in the 4 days following immunization, 
namelylocal reaction includinginjection site tenderness in 2% to 30% and induration in less or equal 
to 2%; and systemic reactions including, diarrhea in less or equal to 13% of children and adults 1 to 
29 years of age, irritability in less than or equal to 12% of children 1 to 10 years of age, headache 
inless than or equal to 11% of children and adults 11 to 29 years of age, vomiting; loss of appetite 
and lethargy in less than or equal to 10% of thevaccine recipients and fatigue, fever (body 
temperature = 38°C) in 2% to7%, and myalgia, arthralgia in less than or equal to 1%  (72). All adverse 
reactions following immunization were transient and resolved without sequelae.
The vaccine must not be administered to subjects with known hypersensitivity to any component of 
the productor to subjects having shown hypersensitivity after previous administration of the vaccine. 
It should not be used insubjects with acute infectious diseases and/or ongoing progressive illnesses. 
In case of fever with temperature of at least 38°C or active infection immunization should be 
delayed. Pregnant women should not be immunized since effects of vaccine on the fetus are 
unknown. Lactating women also should not be given the vaccine since it is not known whether the 
vaccine is excreted in human milk. Administration of the vaccine to subject with impaired immune 
responses may not induce an effective response.
After a pilot phase, the vaccine was introduced in three African countries in 2010. These included 
Burkina Faso, Mali and Niger covering a total population of 18 million persons. The AEFI surveillance 
was passive and active in one health district in Burkina Faso (38; 71). Passive surveillance revealed a 
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total of 1807 AEFIs, including 44 serious events reported from 18.4 million people vaccinated in the 3 
countries during introduction. This corresponds to a reporting rate of 9.8 AEFIs per 100 000 people 
vaccinated. Fever (39.2%) and local reactions (28.4%) were most commonly reported AEFIs. Based 
on a review by national expert committees in each country, only 3/44 serious AEFIs were classified 
as possibly or probably related to vaccination (1 case each of acute exanthematous pustulosis, 
bronchospasm, and vomiting). In addition, during the pilot phase another 4 serious events were 
classified as possibly or probably related to vaccination (bronchospasm, meningitis-like syndrome, 
vomiting, and urticarial).
Active surveillance for 12 pre-identified syndromes was conducted for 52 days (10 days during the 
vaccination campaign and 42 days after) in 16 health-care facilities in which approximately100 000 
people had been vaccinated (71). A total of 71 episodes of these syndromes were investigated, of 
which the most common were convulsions (32 cases), urticaria (18) and bronchospasm (14). The 
national expert committee of Burkina Faso classified these cases as coincidental.A total of 2022 
pregnant women vaccinated in Burkina Faso and Mali have also been followed to collect data on 
AEFIs and pregnancy outcomes.
AEFI surveillance as part of pharmacovigilance in Cameroon
The Republic of Cameroon, with a population of about 20 million in 2012 is situated in central Africa. 
It is organized in 10 health regions and was subdivided into 181 functional health districts in 2012, 
each of them having a given number of health areas (78). Each health district and health area has a 
district hospital and Integrated Health Centers respectively. The quality of health care is generally 
low. Major health problems include reproductive health problems, malaria, HIV/AIDS, tuberculosis, 
other infectious diseases and cardiovascular diseases.The main barriers limiting access to health care 
services include inadequacy of human, material and financial resources, poor planning, geographic 
and cultural inaccessibility to health care and a poor health information system. Strategies to 
overcome these barriers include reinforcing the health system, preventing maternal and child 
mortality, health promotion, and diseases control through health programs.
Pharmacovigilance is part of the health system in Cameroon. It is in charge to organize continuous 
surveillance of safety and efficacy of drugs and vaccines used in clinical practice and in public health 
programs but its activities are still very limited (79). Presently only the EPI is implementing 
pharmacovigilance as part of its activities (80). Even there, the minimum resources to adequately 
insure surveillance activities are provided only for a given proportion of vaccination campaigns and 
mostly by international partners.This should be a point from where to learn in order to build the 
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system in other health programs and in clinical practices. From previous campaigns surveillance 
activities; low reporting and investigation rate, ignorance, lack of motivation, and lack of training 
have been identified as main barriers to AEFI surveillance.Among other interventions, supervision 
has been judged to be the most efficient in improving the training, the awareness as well as AEFIs 
reporting and investigation rates (78). Figure 1 shows the AEFI reporting and the investigation 
system framework in Cameroon.
The vaccination campaign against meningitis A that took place in 2012 had as part of its activities 
AEFI surveillance. It targeted more than 2 million persons aging 1 to 29 years old in all 27 health 
districts of Adamaoua and North West health regions. The AEFI surveillance was implemented for 56 
days including 14 during the campaign and 42 after the campaign. 
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Figure 1: Flow of detection, reporting and investigation of AEFIs during vaccination campaigns in 
Cameroon
Chapter 2: Rationale and Research Question
Vaccination is one of the health care interventions with the most favorable cost-effective and risk 
ratios. Vaccines used as the prevention of vaccine-preventable diseases are those that have proven 
effectiveness and safe in clinical trials and those satisfyingthe WHO criteria for prequalification. 
Whatever the performances of clinical development phases of a vaccine are, these cannot detect all 
vaccine-related AEFIs. While it is unrealistic to think that post-registration monitoring can detect all 
AEFI occurring during this phase, it is recommended that it should detect, report, investigate and 
respond to all serious AEFIs, cluster AEFI, suspected signal, suspected immunization error and those 
that cause concern to the community.
In Cameroon, AEFI surveillance is part of the expanded immunization program and 
pharmacovigilance system but these activities are mainly implemented in vaccination campaigns. 
Even during these campaigns, available resources are insufficient to adequately cover minimum 
planned activities. The national laboratory drug quality control is not able to conduct quality 
assessment of vaccines and diluents.Very little importance and rigor are given to staff’s training and 
results of AEFI surveillance. In routine EPI, about 600,000 pregnant women and more than 800,000 
children receive yearly 12 antigens with 9 of these antigens being administered in three doses.Less 
than 50 AEFIs cases have been reported in EPI for each of the 3 past years and in all of these years 
neither timeliness nor the completeness was satisfactory.Each year, at least five immunization 
campaigns are conducted with an estimate of about 15 million doses administered to children, 
women of child bearing age, and other groups.During these campaigns, underreporting, low 
completeness, timeliness and investigation rates characterize AEFIs surveillance. So, at the end of a 
campaign, it is very difficult to conduct proper data analyses and causality assessment and draw 
conclusions about vaccine safety profile.
The described landscape highlights the need to identify interventions that can help improve 
performances of AEFI surveillance.We believe that theseinterventions can havea better effect on 
vaccines pharmacovigilance if ittargetstheoperational level of thehealth system andtheAEFI 
reporting.
The present PhD was conducted to evaluate the performances of AEFIs monitoring during 
vaccination campaigns in Cameroon, the safety profile of the new vaccine during immunization 
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campaign and the effectiveness of efficient supervision of health personnel of sending SMS to health 
personnel to improve performances of monitoring AEFIs. 
The results could be used to improve post registration AEFI surveillance and increase the availability 
of information on vaccine safety during this phase and the opportunities to properly respond to 
when needed. The MenAfriVacTMisanewly developed and introduced in Africa.It is known to be safe 
given itssafety profile described from clinical trials results but verylittle informationisavailable to 
update itssafety profile since it is being used for immunization campaigns.
The study collected information from avaccination campaignwhich took placein Cameroonin 
December 2012and frompublished data of the clinical trial phases of the MenAfriVacTMand on 
safetyof the vaccineduring otherimmunizationcampaigns conducted in the African belt with this 
vaccine.
The research questions were as follows;
1. What was the safety profile of the MenAfriVacTM vaccine in the vaccination campaign 
organized in Cameroon in December 2012
2. Does sending a weekly standardized SMS to health workers in charge of AEFI surveillance in 
health facilities or conducting standardized supervision of these personnel using skilled 
supervisors result in higher AEFI reporting rates than the routine AEFI surveillance activities 
(i.e., “no intervention”)?
3. What is the magnitude of the difference in the AEFI reporting rates between clinical trials 
and vaccination campaigns with MenAfriVacTM vaccine? What are the implications of this 
magnitude in the safety profile of the vaccine described in immunization campaigns?
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Chapter 3: OBJECTIVES
3.1 General objective
To assess the safety profile of MenAfrivacTMand identify sustainable interventions that can 
contribute to improvepharmacovigilance during mass immunization campaign in Cameroon.
3.2 Specific objectives
1. To investigate the safety profile of the vaccine MenAfrivacTM in the mass immunization 
campaign against meningococcal meningitis organized in Adamaoua and North West Health 
regions of Cameroun in December 2012 
2. to assess the effect on AEFI reporting, after the meningitis vaccination campaigns with 
MenAfrivacTM,of sending a weekly standardized SMS to health workers in charge of AEFI 
surveillance in health facilities or conducting standardized supervision of these personnel 
using skilled supervisors
3. To comparethe incidence and distribution of MenAfrivacTMAEFIsreported during clinical trial 
phases to that reported during immunization campaigns
Chapter 4: Methodology
4.1 Study areas
4.1.1 The field phase 
The field phase of this study was conductedduring the immunization campaign organized in 
Adamaoua and North West health regions in Cameroon in December 2012 and January 2013.In 
2012, the Adamaoua health region had 8 health districts and 73 health areas.In the same period, the 
North West Health region had 19 health districts and 213 health areas.Figure 2 presents the location 
of the two targeted health regions on the Cameroon map. 
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Table II: Distribution of health districts and immunization campaign targeted population in the 
Adamaoua health region (Source: EPI, MOH, Cameroon)
N° Health district Number of 
health areas
Targeted 
population 
01 Bankim 06 82’643
02 Banyo 07 137’783
03 Djohong 04 61’722
04 Meiganga 11 131’162
05 Ngaoundéré rural 14 167’594
06 Ngaoundéré urbain 04 207’019
07 Tibati 15 156’645
08 Tignère 12 97’472
TOTAL 73 1’042’040
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Table III: Distribution of health districts and immunization campaign targeted population in the 
North West health region (Source: EPI, MOH, Cameroon)
N° Health District Number of 
health areas 
Targeted  population
01 Ako 06 43’210
02 Bafut 13 30’645
03 Bali 06 44’000
04 Bamenda 17 23’072
05 Batibo 13 230’442
06 Benakuma 08 55’272
07 Fundong 11 38’164
08 Kumbo East 19 87’714
09 Kumbo West 19 119’788
10 Mbengwi 16 64’464
11 Ndop 15 37’435
12 Ndu 09 142’298
13 Njikwa 06 56’172
14 Nkambe 14 12’634
15 Nwa 05 84’323
16 Oku 10 40’383
17 Santa 09 60’366
18 Tubah 10 48’916
19 Wum 12 36’870
TOTAL 218 1’218’733
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Figure 2: Cameroon map highlighting the two Health Regions targeted by the study: The 
Adamaoua and North West regions.
4.1.2:The Office phase 
Preparatory activities and data management were conducted by the Cameroon Ministry of public 
health in Yaounde at the Departmentof drugs and pharmacy and the Division of Health Operations 
Research, and by Swiss TPH, Basel, Switzerland. One part of the study involved a systematic review 
of the safety profile of MenAfriVacTM with information collected from themeningitis vaccine project 
website,the Medline (PubMed) and Embase data bases. 
4.2 Study population anddesign
4.2.1 AEFI incidence and distribution duringMenAfrivacTM immunization campaign in Cameroon 
The target population of the study was all persons aged between 1-29years that were vaccinatedin 
the Adamawa and North West health regions. This population was estimated at 2'054'989 (756’350 
in the Adamaoua region and 1 298 639 in the North West region) representing about 70% of the 
total population.
The detection of AEFI was done athealth facilityand community levels.It was a passive detection with 
one thirdof the health facilities stimulated through supervision andone third using standardized 
SMS.The reporting formsof allreported caseswere reviewedusinga validated gridto collect dataon 
health facility, patient, immunization and AEFI characteristics.
4.2.2 Effects of SMS or supervision on AEFI reporting rates 
Officially created and functional health facilities, covered by at least one mobile telephone network 
with at least one health personnel appointed for AEFI surveillance, were included. Health personnel 
working in the included health facilities and designated in charge of AEFI surveillance in the 
MenAfrivacTM campaign were targets of interventions. 
The study wasa randomized, controlled trialinvolving threegroups. 
i) The SMS group: In which standardized SMS were sent once in English and once in French on 
weekly basis to AEFIs focal points in health facilities. The ‘’delivery report’ ’function of the 
mobile phone was used to verify if the message was received and viewed.
ii) Supervision group: each week, a trained nurse (on supervision and AEFI surveillance) visited 
each health facility assigned to the supervision group on Monday or Tuesday to supervise 
the focal points of AEFI detection and reporting using a standardized grid. Weaknesses were 
corrected by supervisors using standardized guidelines. The supervision visits were verified 
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by checking stamps and signatures of the heads of the health facility on supervisor’s mission 
orders. 
iii)  The control group: health facilities received no additional AEFI-related interventions apart 
from what all health facilities normally receive during a vaccination campaign, namely pre-
campaign training on AEFIs surveillance, passive AEFI monitoring during the campaign and 
42 days after and monthly sensitization of health facility teams during health district 
coordination meetings. 
The endpoint was the AEFI incidence rate.
4.2.3. Comparison of AEFI incidence and distribution between clinical trials and immunization 
campaigns 
This was a systematic review in which all study participants exposed to MenAfrivacTMin clinical trials 
or immunization campaigns were targeted. 
All published studies reporting adverse events following MenAfrivacTM administration during clinical 
trials and immunization campaigns were searched from the Meningitis vaccine project website, 
Medline and Embase. Data were selected using a grid on study and participants’ characteristics, 
immunization and surveillance procedures and characteristics of reported AEFIs. The incidence rate 
(IR) of the general, local, systemic, serious AEFIs and types of reported AEFIs were estimated and 
compared between clinical trials and immunization campaign studies using the incidence rate 
difference (IRd). 
4.3. Study procedures
Surveillance guidelines and tools were adapted from those developed and used during previous 
campaigns(38, 65, 71). Report forms were standardized in English and French. Data were extracted 
from these forms using a grid conceived to collect information on the reporting health facility, 
patient’s age and sex, vaccine and diluent batch number, administration procedures, dates of 
vaccination, symptom onset and of reporting, exposure to other drugs, actions taken to manage 
AEFI, outcome and seriousness of the AEFI and status of the reporting health personnel. 
During the immunization campaign, baseline information was collected per health facility on the 
health region, health district, category of health facility (e.g., integrated health center vs. other), and 
type and position of health professionals designated as the AEFIs focal point. Information on mobile 
telephone network coverage was also obtained and districts supervisors selected. In addition, the 
number of AEFIs reported before the interventions were implemented was collected at North West 
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and Adamaoua Regional Delegations of Public health. During the two-week period following the 
campaign, districts focal points were trained and assignment of health facilities to intervention 
groups proceeded. Interventions were implemented and outcomes assessed as described in chapter 
6.
For the systematic review, data were extracted using a validated grid from a previous study(26) Data 
were extracted by one reviewer and compiled in an excel table. A second reviewer cross-checked 
one by one all extracted data comparing data in the excel table to filled data extraction forms and 
full texts of articles. In case of discrepancies, corrections were made from the full text article. The 
following characteristics were extracted from each article: characteristics of the study (study design, 
year of publication, study country, health care setting, type of resource available, source of the 
report, name of the first author), characteristic of the study population (size, age group, inclusion 
criteria, exclusion criteria, number of pregnancies exposed), phase of the vaccine development 
(phase 1, 2, 3, 4 clinical trials, mass immunization campaign, routine EPI), characteristics of the 
vaccination (antigen, dose, administration procedure, other vaccine or drugs concomitantly 
administered, first or second dose), characteristics of the AEFI surveillance system (case definition of 
AEFI, case definition of serious AEFI, type of surveillance (active, passive stimulated or not), 
surveillance duration, type of AEFI investigated), characteristics of reported AEFIs [total number, 
number of serious, number of local reaction, number of systemic reaction, number of AEFIs per age 
group, number of AEFI per type, number of clusters AEFIs, number and type of AEFIs among 
pregnant women, number of serious AEFIs investigated, number of vaccine product-related reaction, 
number of vaccine quality defect-related reaction, number of immunization error-related reaction 
(formerly “program error”), number of immunization anxiety-related reaction, number of 
coincidental events]. 
4.4. Statistical methods
For each objective,data wereextractedeither from AEFIs report forms orfrom published 
articlesusinga grid.These datawereenteredeither onEpiInfoversion3.5.3orin Excel 2010, 
crosschecked, cleanedandanalyzedeitherdirectly ortransferred toStata10(Texas,2009)or19IBM 
SPSSfor analysis.
The MenAfrivacTMsafety profile during vaccination campaigns was described by estimatingthe 
incidence rateof overall and types of AEFIby time after injection, age group and health region. AEFIs 
symptoms were aggregated in SOC (System Organ Class) and their proportions were estimated and 
compared per age group, health region, vaccine and diluent batch. This comparison was made firstly 
by performing unadjusted relative risk with 95% confidence interval. Multivariate logistic regression 
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was further used to adjust for potential confounding variables. To control MEER (maximum 
experimentwise error rate) due to multiple testing, p-values were adjusted based on Bonferroni 
method. 
To assess the effects of SMS or supervision on AEFI reporting rates, the incidence rate of reported 
AEFIs was estimated per study group. The effect of interventions was compared between study 
groups by estimating the  rate ratio (RR) and the risk relationship. The significance of the difference 
was estimated using the Z test, confidence intervals and p value. Poisson regression model was used 
to estimate the effect of interventions on reported AEFI on incidence rates, after adjusting for 
potential confounders, namely the cumulative number of AEFIs reported from Week 1-4, the health 
region, the type of health facility and position of the health professionals acting as the AEFI focal 
points
In the study aiming at Comparing AEFI incidence and distribution between clinical trials and 
immunization campaigns; theincidencesof overall, local, systemic, serious and types of AEFIs were 
estimated and compared between clinical trial phases and immunization campaignwith 
MenAfrivacTM.The comparison was made by estimating incidence rate difference with 95% IC. 
More Details of statistical methods are presented in chapters 5, 6 and 7. 
4.3 Ethical consideration
The work was conducted according to the International Conference on Harmonization (ICH) Good 
Clinical Practice (GCP) guidelines, and the 2008 version of the Declaration of Helsinki.
The confidentiality and privacy of the patients were maintained, as the variables that could lead to 
their identification in the AEFI source documents were not transferred into the data extraction 
forms. 
In order to fully comply with ethics in clinical research, before being included in a study, all 
participants (hospital focal points for AEFI surveillance) were informed and consented prior to their 
inclusion. All studies were approved by the Cameroon National Ethics Committee (approval number: 
208/CNE/SE/2012) and the randomized trial was registered into the Pan African Clinical Trial Registry 
database with a unique identification number PACTR201201000454298 (www.pactr.org).
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Chapter 5: Incidence and type of adverse events during mass 
campaign with a conjugate group a meningococcus meningitis 
vaccine (MenAfrivac™) in Cameroon
AUTHORs: Jerome ATEUDJIEU, Beat STOLL, Georges NGUEFACK-TSAGUE, Marcellin NIMPA 
MENGOUO, Blaise GENTON. 
ABSTRACT
Purpose 
To describe the incidence and type of adverse events following immunization (AEFIs) with a new 
conjugate vaccine againstmeningitis A (MenAfrivac™)in a Cameroonian vaccination campaign. 
Methods
The campaignwas heldin December 2012 and the AEFIs surveillancefrom December-January 2013. 
This was both a passive and stimulated surveillance. Incidence rates of overall and serious AEFIs 
were estimated as well as AEFIs incidence rates by type, age group and region. AEFIs symptoms were 
aggregated in SOC. 
Results 
Of 2’093’381 persons vaccinated, 1’352 AEFIs were reported. Of these 228 (16.9%) were excluded 
because they did not meet inclusion criteria.Among the remaining 1’124 (83.1%), the incidence rate 
was 53.7 AEFIs/100’000 doses administered/8weeks. Of 82 serious AEFIs reported, 52 (63.2%) met 
the case definition. Twenty-three (28.1%) were investigated, of which 4 (17.4%) were probably 
related to the vaccination (incidence rate: 0.2 AEFIs/100’000 doses administered/8weeks). Fever was 
the commonest AEFI with 626 cases (incidence rate: 31.4 AEFIs/100’000 doses 
administered/8weeks). Proportions of subjects with different primary SOC disorders varied by age 
group, gastro-intestinal and respiratory being more frequent in children aged <4years and 
neurological and general conditions more so in adults for example. 
Conclusion 
This studydid not detect any new safety signal norincreased incidence of seriousAEFIs compared to 
previous mass immunization campaign withMenAfrivacTM. There were age differences in incidence 
and type of AEFIs that are probably related to different background incidence of diseases and 
different susceptibilities or reporting in these different age groups.
Key words: AEFI incidence, immunization campaign, MenAfrivacTM,Meningitis A, Cameroon 
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BACKGROUND
AEFIs (Adverse Events Following Immunization) surveillance is essential to ensure vaccine safety. It is 
expected to provide information on incidence, distribution and risk factors for expected and 
unexpected serious and minor AEFIs (1; 2; 3; 4). Surveillance of AEFIsis thus an integralpart of 
anyimmunization activity.(32; 90; 91).But expectations are still not met because of underreporting, 
low completeness, untimelinessand poor data quality (8; 9). Consequently available informationon 
marketed vaccine safety is limited. A number ofstudiesidentifiedinterventionsandstrategies to 
improvethe situation(10; 11; 12; 13; 14). More operational research is needed, particularly in Africa, 
to identify effective interventions for AEFI surveillance performance(15; 16; 17; 18).
Since its introduction in 2010, more than 100 million doses of MenAfrivacTMhave been administered 
to people in10 African countriesofthe meningitis belt by the end of 2012(19). However, published 
information on AEFIs distribution covers onlyabout 18million people vaccinated(20). Disseminating 
information onvaccine safetyfor allvaccinated casesis highly recommended as this guides actions 
aiming at improving safety of the vaccine, and hence overall benefit. 
The objective of the present studywas to describe the incidences and type ofAEFIsreported in the 
2012 mass immunization with MenAfrivacTMagainstmeningitisAin Cameroon. 
METHODS
Ethical review 
This study was approved by the Cameroon National Ethics Committee with 208/CNE/SE/2012 as 
ethical clearance number.
Study design 
This was a descriptive and analytical study based on data collected from AEFIs report forms using a 
preconceived grid. Passive and active stimulated AEFIs surveillance were conducted in health 
facilities and in vaccination sites over a period of two weeks during the vaccination campaign and six 
weeks thereafter. Incidence and types of AEFIs were described by time after injection, age group and 
health region. AEFIs symptoms were aggregated in SOC and their proportions were estimated and 
compared per age group, health region, vaccine and diluent batch.
Preparatory activities 
Members of the AEFI multidisciplinary Monitoring Committee were appointed by the Ministerof 
Public Health. They updated AEFI surveillance guidelines, ordered necessary supplies, trained 
central, regional and district supervisors. 
Case definition and selection criteria 
AEFI case definitions were adapted from those used during previous campaigns(21; 22; 23). Allcases 
reported from North West and Adamaoua health regions during the surveillance period were 
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eligible.Cases with a report form lacking record of symptom,date of vaccination orsymptomonset 
wereexcluded. Caseswith datesofsymptoms onset prior tovaccination and variables with ambiguous, 
confusing or unintelligible description of symptoms, dates or health districts regions were excluded 
too.
Surveillance and data collection tools 
Surveillance guidelines and tools were adapted from those developed and used during previous 
campaigns(21; 22; 23). Report forms were standardized in English and French. Data were extracted 
from these forms using a grid conceived to collect information on the reporting health facility, 
patient’s age and sex, vaccine and diluent batch number, administration procedures, dates of 
vaccination, symptom onset and of reporting, exposure to other drugs, actions taken to manage 
AEFI, outcome and seriousness of the AEFI and status of the reporting health personnel. 
Surveillance activities 
AEFI surveillance activities followed a path: from the vaccination site to the health facility, then 
district, region and central level. Regions, districts, health facilities and vaccination teams were 
supervised by supervisors from central, regional and district levels. Regional delegations of public 
health and district health services were in charge ofreceiving anddistributing 
surveillanceresources,collecting,compiling and sending AEFI reports to upper levels and investigating 
serious AEFIs. 
At the health facility level, surveillance was conducted over the two weeks of the campaign and six 
weeks after. It included detecting cases during consultation and in registers, reporting these cases 
and investigating serious ones. Focal points of two third of health facilities were stimulated for the 
last four weeks of surveillance using enhanced supervision or SMS (11).
At the community level, surveillance activities included sensitizing people two weeks before and 
during the surveillance period to detect AEFI and what to do if it occurs. At this level, AEFIs reporting 
was conducted by vaccination teams in vaccination sites during the two weeks of the vaccination 
campaign. 
At the central level, weekly meetings of the AEFI monitoring committee were held to review report 
forms, stimulate reporting, ensure that all serious AEFIs were investigated and causality assessment 
performed. 
Statistical analysis 
The AEFIs incidence rate was estimated over a period of 8-week post-injection per 100’000 vaccine 
doses administered. Overall and serious AEFIs incidence rates were estimated; as were AEFI 
incidence rates per, type, time after injection, age group, and region. The Medical Dictionary for 
Regulatory Activities (MedDRA) was used to code and retrieve reported events (24; 25). For each 
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AEFI, each sign or symptom (low level terms) was assigned to a Preferred Term (PT). The process was 
implemented by a qualified physician. Each PT was automatically assigned to primary SOC using 
Stata software. PTs that were only represented in one SOC were automatically assigned that SOC. 
When a PT was linked to more than one SOC, it was assigned to a primary SOC selected as 
recommended in MedDRA Guideline (25). Each SOC was considered as a dependent variable, and 
modelled including the following exploratory variables: age group, region, vaccine and diluent batch. 
A bivariate analysis was performed first using unadjusted relative risk with 95% confidence interval. 
Multivariate logistic regression was further used to adjust for potential confounding variables. When 
the variable of interest was one of the above repressors, the others were considered as confounders 
in the corresponding regression model. The strength of risk in multivariate regression was then 
quantified using adjusted relative risk with 95% confidence interval. P-values were computed using 
Chi-squared test; and since age group was ordinal variable, Gamma test of association was used. To 
control MEER (maximum experimentwise error rate) due to multiple testing, p-values was adjusted 
based on Bonferroni method (26). Data were entered in Epi-Info version 3.5.3, and analyzed using 
Stata version 10 and IBM SPSS version 19.
RESULTS
I. Incidence of reported AEFIs
AEFI surveillance activities started with the campaign on December 3, 2012 and ended on January 
27, 2013. In total, 2’093’381doses of MenAfrivacTMwere reported to have been administered in 27 
health districts. Table 4 presents the batches and number of doses of vaccines and diluents used. 
The 1’352 reported AEFIs included 1’144 (84.6%) from the North West region and 206 (15.2%) from 
the Adamaoua region. For 2 (0.2%) AEFIs, the region were not specified. Table 5 presents the 
distribution of reported AEFI per health district and region. 
In total228 (16.3%)AEFIswere excludedfor the following reasons: date of vaccination missing (120; 
10.5%), date of symptom onset missing (33; 2.9%), no symptom was reported (22; 2.0%), symptom 
onset was prior to vaccination date (53; 4.7%). 1’124 (83.1%) reported AEFIs were analyzed (53.7 
AEFI/100’000 doses administered/8 weeks). Of 1’101 with the gender variable filled, 507 (46.1%) 
were males and 594 (53.9%) females. Seven (1.2%) AEFIs occurred inpregnantwomen .
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Table IV: distribution of number of doses of vaccines and diluents used per batch
Vaccine/diluent batch Batch number Number of doses used Percentage of the 
total of doses used 
Vaccine 
Batch A 127O20100Z 69’410 3
Batch B 127O20110Z 845’500 37
Batch C 127O20120Z 882’310 38
Batch D 127O20130Z 520’180 22
Total 2’317 ‘400 100
Diluent 
Batch A 10812006CZ 1’185’720 51
Batch B 10812006BZ 1’131’680 49
Total 2’317’400 100
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Table V: Distribution of reported AEFI per health district and health region
District Number of doses 
administered
Number of AEFI 
reported
Incidence rate/100’000 doses 
administered/8weeks
Adamaoua 
Bankim 61’686 25 40,5
Banyo 94’704 18 19.0
Djohong 59’605 28 47.0
Meiganga 105’648 6 5.7
Ngaoundere Rural 140’985 26 18.4
Ngaoundere Urbain 164’180 59 35.9
Tibati 114’484 40 34.9
Tignere 71’394 4 5.6
Total 812’686 206 25.4
North West
Ako 33’528 21 62.6
Bafut 43’058 18 41.8
Bali 16’765 55 328.1
Bamenda 218’561 83 37.9
Batibo 49’803 220 441.7
Benakuma 38’227 62 162.2
Fundong 85’426 36 42.1
Kumbo East 117’033 12 10.3
Kumbo West 68’465 40 58.4
Mbengwi 38’493 16 41.6
Ndop 148’028 14 9.5
Ndu 52’863 11 20.8
Njikwa 13’621 13 95.4
Nkambe 83’230 179 215.1
Nwa 39’993 22 55.0
Oku 55’589 70 125.9
Santa 49’911 20 40.1
Tubah 43’109 24 55.7
Wum 84’992 168 197.7
Health district missing 60
Total 1’280’695 1’144 89.3
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II. Distribution of reported AEFIs
a) Incidence of serious AEFIs reported
AEFIs seriousness was reported for 1’120 (99.6%). Of these, 82 (7.3%) serious AEFIs were reported 
leading to an incidence rate of 3.9/100’000 doses administered/8weeks. After review by the 
monitoring committee, 30/82 (36.6%) were considered minor AEFIs. Of the remaining 52 
(2.5AEFIs/100’000 doses administered/8weeks), 29 (55.7%) were not assessed for causality because 
of insufficient information. The vaccine relatedness was thus conducted on 23/52 (44.2%) serious 
AEFIs among which 4 (incidence rate: 0.2 AEFI/100’000 doses administered/8weeks) were classified 
as probably related to the vaccine and 19 unrelated (coincidental). The 4 probably related cases 
included one case of hypersensitivity and 3 cases of anaphylactic shock. The 19 unrelated cases were 
classified as coincidental.
b) Distribution of AEFIs per type and time from vaccination. 
Table 6 shows the types of AEFIs (symptoms and signs) reported during the surveillance period and 
their incidence rates. These included 183 local reactions (10.1%) and 1’811 (90.9%) systemic 
reactions, summing up to 1’994. Fever had the highest incidence rate. Some report forms included 
more than one AEFI type. Figure 3 shows the number and types of AEFIs reported per week. The 
number was highest in the first weeks of surveillance. The first two Weeks of surveillance were 
overlaid withimmunization activities. 
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Table VI:  Incidence rates of signs and Symptoms of reported AEFIs during the surveillance period 
(over an 8-week period)
Signs and symptoms Number of AEFI cases 
with the symptom or 
sign
Cumulative incidence /100’000 
doses administered/8weeks
Local 
Pain at the injection site 137 6.8
Pain in the injected arm 05 0.3
Swelling of the injection site 37 1.8
 Swelling of the injectedlimb 04 0.2
Total 183 9.2
Systemic
Fever 626 31.4
Headaches 184 9.2
Running nose 180 9.0
Cough 150 7.5
Generalized pruritus 118 5.9
Vomiting 98 4.9 
Diarrhea 7 7 3.9 
Convulsions 18 0.9
Sudden faintness afterinjection 05 0.3
Unconsciousness 4 0.2
Other symptoms 351 17.6
Total 1’811 90.8
Total reported symptoms 1’994 100.0
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Figure 3: Weekly number of the different types of AEFI during the surveillance period
 Legend: W: week 
c) Distribution of reported AEFIs categorized by SOC
Table 7 shows the distribution of AEFIs per SOC. The SOC ‘infection and infestation’ had the highest 
rate (17.4/100’000 doses administered/8weeks) followed by ‘Nervous system disorders’ 
(9.8/100’000 doses administered/8weeks). 
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Table VII: Incidence of reported AEFIs categorized by SOC
N° SOC Frequency Cumulative incidence 
/100’000 doses/8 weeks 
administered
3 Infections and infestations 364 17.4
2 Nervous system disorders 206 9.8
3 Respiratory, thoracic and mediastinal disorders 203 9.7
4 Gastrointestinal disorders 162 7.7
2 General disorders and administration site 
disorders
139 6.6
7 Immune system disorders 127 6.1
5 Pregnancy, puerperium and perinatal conditions 2 (2/7) NA*
* 7 cases of pregnancies were reported.
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d) Distribution of AEFIs reported per age group 
A total 422, 320, 260 and 25 AEFIs were reported in age groups 1-4 years, 5-15 years, 16-29 years 
and ≥ 30 years respectively. 422’277, 824’067 and 847’037 doses of MenAfrivacTMwere administered 
to the age groups 1-4, 5-15 and 16-29 respectively. The AEFI incidence rate per 100’000 doses 
administered/8weeks was thus 100.0, 38.8 and 30.6 for age groups 1-4, 5-15 and 16-29 respectively. 
Taking the age group 1-4 years as reference, the AEFIs incidence rate was lower in age groups 5-15 
years [RR=0.39 (0.34-0.45), p<0.001] and 16-29 years [RR=0.30 (0.26-0.35), p<0.001]..
e) Distribution of AEFIs reported by health region 
Table 5 shows the distribution of AEFIs reported per health district and region. 206 AEFIs were 
reported in the Adamaoua region for 812’692 doses administered (25.4/100’000 doses 
administered/8weeks) and 1’144 for 1’280’695 doses in the North West region (89.3/100’000 doses 
administered/8weeks). The incidence rate of AEFIs for the North West region was higher than that 
for the Adamaoua [RR=3.6 (2.8-3.8), p<0.0001].
III) Comparison of proportions of AEFIs categorized by SOC reported between age groups
Table 8 presents the comparisons of proportions of reported AEFIs categorized by SOC between age 
groups. The proportion of reported ‘Gastrointestinal disorders’ was significantly lower in age groups 
5-15 and 16-29 years than in age group 1-4 years [aRR=0.55(95% CI 0.33-0.91) and 0.47(0.29-0.77) 
respectively]. The same was true for the proportion of reported ‘Respiratory, thoracic and 
mediastinal disorders’ [aRR= 0.47 (0.29-0.74) and 0.19 (0.11-0.33) respectively]. Proportions of 
‘General disorders’ and ‘administration site conditions’ were significantly higher in age group 16-29 
[aRR= 3.00(1.69-5.34)]. Lastly the proportion of ‘Nervous System Disorders’ was higher in age groups 
5-15 and 16-29 years [aRR=2.36 (1.44-3.88) and 2.07(1.28-3.37) respectively]. 
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Table VIII: Comparison of proportions of AEFIs (categorized by SOC) reported per age group.
SOC  Age groups Total SOC (%)
[1-4] [5-15]    [16-29]
P-value Bonferroni 
adjusted p 
value 
P-value Bonferroni 
adjusted p 
value
Gastrointestinal disorders
Number n (n/N%) 85/464 (18.3) 38/343 (11.1) 35/362 (9.7) 158/1’169 (13.5)
RR (95%CI) 1 0.53 (0.35-0.81 0.003 0.43 (0.28-0.65) <0.001
aRR (95%CI) 1 0.55 (0.33-0.91) 0.020 0.040 0.47 ( (0.29-0.77) 0.003 0.006
General disorders and administration site conditions 
Number n (n/N %) 25/464 (5.4) 34/343 (9.9) 76/362 (21.0) 135/1’169 (11.5)
RR (95%CI) 1 1.893 (1.10-3.23) 0.020 4.25 (2.64-6.85) <0.001
aRR (95%CI) 1 1.64 (0.87-3.12) 0.130 3.00 (1.69-5.34) <0.001 <0.002
Infections and infestations
Number n (n/N%) 146/464 (31.5) 107/343 (31.2) 106/362 (29.3) 359/1’169 (30.7) 
RR (95%CI) 1 0.95 (0.7 (0-1.29) 0.740 0.7 (9 (0.58-1.07) 0.130
aRR (95%CI) 1 1.00 (0.68-1.46) 0.990 0.84 (0.58-1.21) 0.340
Nervous system disorders
Number n (n/N %) 44/464 (9.5) 80/343 (23.3) 77 /362 (21.3) 201/1’169 (17.2)
RR (95%CI) 1 2.86 (1.92-4.28) <0.001 2.34 (1.57-3.49) <0.001
aRR (95%CI) 1 2.36 (1.44-3.88) <0.001 <0.002 2.07 (1.28-3.37) 0.003 0.006
Immune system disorders
Number n (n/N %) 36/464 (7 .8) 41/343 (11.9) 44/362 (12.2) 121/1’169 (10.4)
RR (95%CI) 1 1.58 (0.98-2.53) 0.060 1.49 (0.94-2.38) 0.090
aRR (95%C 1 1.53 (0.85-2.76) 0.160 1.67 (0.96-2.92) 0.070
Respiratory, thoracic and mediastinal disorders 
Number n (n/N %) 128/464(27.6) 43/343 (12.5) 24/362 (6.6) 195/1’169 (16.7 
RR (95%CI) 1 0.36 (0.24-0.52) <0.001 0.16 (0.10-0.26) <0.001
aRR (95%CI) 1 0.47 (0.29-0.74) <0.001 <0.002 0.19 (0.11-0.33) <0.001 <0.002
Total age group (N) 464 343 362 1’169
RR (95%CI): Relative risk with 95% confidence interval; aRR (95%CI): adjusted Relative risk with 95% confidence interval. N: Total age group. n: number of cases categorized by SOC. 
SOC: System Organ Class. The p value was adjusted using the Bonferroni method after persistence of significance in multivariate logistic regression; the adjusted variables being 
region, vaccine batch and diluent batch
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IV Comparison of proportions of AEFIs categorized by SOC between regions and vaccine and 
diluent batch
As presented in tables 9, 10 and 11, proportions of AEFIs categorized by SOC did not significantly 
differbetween regions, vaccine batches nor diluent batches, except for ‘Gastrointestinal disorders’ 
which affected more individual cases exposed to diluent batch B compared to batch A 
[aRR=1.93(1.06-3.51)]. 
Table IX: Comparison of proportion of AEFI reported per region, categorized by SOC
SOC Adamaoua North West Total SOC (%)
P value 
Gastrointestinal disorders
Number n (n/total region (N)%) 19/134 (14.2) 139/1’035 (13.4) 158/1’169 (13.5)
RR (95%CI) 1 0.95 (0.56-1.59) 0.830
aRR (95%CI) 1 0.08 (0.01-0.57 () 0.010
General disorders and administration site conditions 
Number n (n/N%) 38/134 (28.4) 97/1’035 (9.4) 135/1’169 (11.5)
RR (95%CI) 1 0.26 (0.17 (-0.40) 0.000
aRR (95%CI) 1 0.83 (0.27 (-2.56) 0.750
Infections and infestations
Number n (n/N%) 33/134 (24.6) 326/1’035 (31.4) 359/1’169 (30.7) 
RR (95%CI) 1 1.43 (0.94-2.17 0.090
aRR (95%CI) 1 1.65 (0.63-4.33) 0.310
Nervous system disorders
Number n (n/N%) 25/134 (18.7) 176/1’035 (17.0) 201/1’169 (17 .2)
RR (95%CI) 1 0.90 (0.56-1.43) 0.650
aRR (95%CI) 1 0.32 (0.07-1.44) 0.140
Immune system disorders
Number n (n/N%) 13/134 (9.7 () 108/1’035 (10.4) 121/1’169 (10.4)
RR (95%CI) 1 1.09 (0.60-2.00) 0.780
aRR (95%CI) 1 0.32 (0.07 (-1.44) 0.950
Respiratory, thoracic and mediastinal 
disorders 
Number n (n/N%) 6/134 (4.5) 189/1’035 (18.3) 195/1’169 (16.7 )
RR (95%CI) 1 4.85 (2.10-11.18) 0.000
aRR (95%CI) 1 0.24 (0.02-2.79) 0.260
Total health regions (N) 134 1’035      1’169
RR (95%CI): Relative risk with 95% confidence interval ;aRR (95%CI): adjusted Relative risk with 95% confidence 
interval.  N: Total health region. n: number of cases categorized by SOC . SOC: System Organ Class. The 
adjusted variables were age group; vaccine and diluent batch.
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Table X: Comparison of proportion of reported AEFIs per vaccine batch that were categorized by SOC
 SOC                                                                Vaccines batch number                                  Total SOC (%)
Batch A Batch B Batch C Batch D
P 
value
Bonferroni adj. 
p value
P value P value
Gastrointestinal disorders
Number n (n/N %) 7/44 (15.9) 18/145 (12.4) 67/534 (12.5) 55/385 (14.3) 147/1’108 (13.3)
RR (95%CI) 1 0.78 (0.30-2.01) 0.61 0.82 (0.35-
1.90)
0.64 1.08 (0.46-2.54) 0.86
aRR (95%CI) 1 0.16 (0.03-1.08) 0.06 0.94 (0.18-
4.7)
0.94 1.18 (0.22-6.13) 0.85
General disorders and administration site conditions
Number n (n/N%) 3/44 (6.8) 43/145 (29.7) 50/534 (9.4) 38/385 (9.9) 134/1’108 (12.1)
RR (95%CI) 1 6.02 (1.77 -20.49) 0.01 1.51 (0.45-5.06) 0.50 1.81 (0.53-6.12) 0.34
aRR (95%CI) 1 2.22 (0.41-12.14) 0.36 0.51 (0.10-2.44) 0.40 0.91 (0.18-4.51) 0.91
Infections and infestations
Number n (n/N %) 16/44 (36.4) 37/145 ( (25.5) 17/534 (0 (31.8) 118/385 (30.6) 341/1’108 (30.8)
RR (95%CI) 1    0.63 (0.31-1.30) 0.21 0.90 (0.47 -1.7) 0.7 1.00 (0.52-1.91) 0.99
aRR (95%CI) 1 0.64 (0.19-2.17) 0.24 0.51 (0.10-2.44) 0.27 0.58 (0.20-1.69) 0.32
Nervous system disorders
Number n (n/N%) 3/44 (6.8) 26/145 (17 (.9) 94/534 (17.6) 7/385 (1.8) 194/1’108 (17.5)
RR (95%CI) 1 3.11 (0.90-10.82) 0.07 3.14 (0.95-10.35) 0.06 3.81 (1.15-12.65) 0.03
aRR (95%CI) 1 0.7 (6 (0.13-4.65) 0.7 2.13 (0.42-10.65) 0.36 1.98 (0.38-10.25) 0.42
Immune system disorders
Number n (n/N%) 8/44 (18.2) 16/145 (11.0) 57/534 ( (10.7 () 39/385 (10.2) 120/1’108 (10.8)
RR (95%CI) 1 0.58 (0.23-1.47) 0.25 0.58 (0.26-1.30) 0.19 0.62 (0.27 -1.42) 0.25
aRR (95%CI) 1 0.96 (0.15-6.03) 0.96 0.85 (0.18-4.00) 0.83 1.42 (0.29-6.95) 0.68
Number n (n/N %) 7/44 ( (15.9) 5/145 (3.5) 96/534 (18.0) 64/385 (16.6) 170/1’108 (15.5)
RR (95%CI) 1 0.20 (0.06-0.66) 0.01 1.25 (0.54-2.88) 0.60 1.30 (0.55-3.04) 0.55
aRR (95%CI) 1 0.07 ( (0.008-0.7 (0) 0.02 0.06 1.84 (0.39-8.70) 0.45 1.02 (0.21-5.13) 0.97 
Total vaccine batch nuber (N) 44 145 534 385 1’108
RR (95%CI): Relative risk with 95% confidence interval; aRR (95%CI): adjusted Relative risk with 95% confidence interval. N: total vaccine batch. n: number of cases categorized by SOC. SOC: 
System Organ Class. The p value was adjusted using the Bonferroni method after persistence of significance in multivariate logistic regression; the adjusted variables being age group; region, 
and diluent batch.adj: adjusted 
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Table XI: Comparison of proportion of reported AEFIs per diluent batch that were categorized by 
SOC
SOC     BATCH A    BATCH B
P value Total SOC (%)
Gastrointestinal disorders
Number n (n/N %) 32/281 
(11.4)
7/530 (13.2) 110/811 (13.6)
RR (95%CI) 1 1.44 (0.93-2.24) 0.10
aRR (95%CI) 1 1.93 (1.06-3.51) 0.03
General disorders and administration site 
conditions 
Number n (n/N %) 42/281 
(14.9)
56/530 (10.6) 98/811 (12.1)
RR (95%CI) 1 0.7 (2 (0.47-1.10) 0.13
aRR (95%CI) 1 1.48 (0.78-2.83) 0.23
Infections and infestations
Number n (n/N %) 81/281 
(28.8)
17/530 (31.1) 252/811 (31.1)
RR (95%CI) 1 1.29 (0.94-1.7 (7 
()
0.12
aRR (95%CI) 1 1.10 (0.7 (5-1.62) 0.61
Nervous system disorders
Number n (n/N %) 51/281 
(18.2)
89/530 (16.8) 140/811 (17.3)
RR (95%CI) 1 0.98 (0.67-1.43) 0.90
aRR (95%CI) 1 1.08 (0.67 (-1.7 
(3)
0.7 (4
Immune system disorders
Number n (n/N %) 34/281 
(12.1)
54 /530 (10.2) 88/811 (10.9)
RR (95%CI) 1 0.88 (0.56-1.39) 0.58
aRR (95%CI) 1 0.82 (0.47-1.42) 0.47 
Respiratory, thoracic and 
mediastinal disorders 
Number n (n/N %) 41/281 
(14.5)
82/530 (15.5) 123/811 (15.2)
RR (95%CI) 1 1.15 (0.7 (6-1.73) 0.50
aRR (95%CI) 1 0.7 (3 (0.46-1.17) 0.19
Total diluent batch (N) 281 530 811
RR (95%CI): Relative risk with 95% confidence interval aRR (95%CI): adjusted Relative risk with 95% 
confidence interval. N: Total diluent batch. n: number of cases categorized by SOC. SOC: System 
Organ Class. The adjusted variables were age group, region, and vaccine batch.
DISCUSSION
The overall incidence rateofAEFIs, reported during the mass immunization campaign against 
meningitis A held in Cameroon in 2012 was 53.7AEFI/100’000 doses administered/8weeks). It was 
3.9 AEFI/100’000 doses administered/8weeks for serious AEFIs with four (0.2 AEFI/100’000 doses 
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administered/8weeks) classified as probably related to the vaccine. The incidences and types of 
AEFIs varied according to age group and region. 
The estimated incidence rate ofAEFIswashigher in this campaign than in previous ones organized in 
Cameroon or in other countries using the same vaccine(21; 22; 27; 23). There are several possible 
reasons for that: i) suboptimal vaccine storage conditions or administration procedures, ii) 
coincidental epidemic illnesses during the campaign surveillance period, or iii) improvedmonitoring 
system. Vaccinesused werepre-qualified by the WHOand this was confirmed by the competent 
departmentsof the Ministry ofPublic HealthofCameroon. Cold chain, vaccine transport and 
administration procedures were closely supervisedand no irregularity was reported(28). Thus the 
high incidence of AEFIs was unlikely due to vaccine quality or program errors. 
Noepidemicwasreportedin any of the targeted regions that could have increased the 
incidenceofAEFIs. The high incidence rate ofAEFIin this campaign was thus morelikely due to the 
improvementof the detection and monitoring system. Indeed,unlike othercampaigns, two thirds 
ofhealth facilitiesinvolved inthis campaignwerestimulated to report AEFIs weekly during thelast 
fourweeks of the surveillance by supervising the health personnel concerned, and sending SMSto 
AEFIs focal pointsin health facilities(11). This reporting enhancement contributed to an increase in 
AEFI reporting rate in the second half of themonitoringperiodduring which the rateis oftenlow. 
Interventions contributing to improve AEFIs reporting rates should bepromoted during immunization 
activities in order to improve thesensitivityof the surveillance and the likelihoodto detectnew AEFIs 
andall seriousAEFIsones.
The incidence rate of seriousadverse eventsreported was in thesame rangeas that in 
previousstudies. However, less than a thirdof these caseswere investigated because either they did 
not meetthe case definition or they lackednecessaryinformationto be appropriately assessed. The 
proportion of coincidental cases(82%)was similar to that reported during campaigns inBurkina Faso 
and Mali (29). Four cases including one case of hypersensitivity reaction and three cases of 
anaphylactic shock were probably related to the vaccine based on the case definition, time lapse 
after immunization, time window of increased risk, the favorable course after adrenaline 
administration, the biological plausibility and exclusion of other causes. These cases were allergic 
reactions, as reported in previous studies (29). Information on these caseswas rather limited; they 
werereported based on symptoms by the vaccination teamsthat were notin a position toperform 
athorough clinical examination because of the emergency of the situation.
Regarding AEFIs types, reported local reactions were minorwiththe highest incidence duringthe first 
week ofsurveillance and the lowest (zero) after week 4 post-immunization(Figure 1). Incidence rate 
was higher than that observed during previous campaigns but lower than that recorded during 
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clinical trials., Indeed, monitoring oflocal reactionsis importantsince it allowsearly detection and 
prevention of some program errors and somaintains populationadhesion to immunization. (22; 21; 
32; 30; 31; 23). Regarding systemic reactions, fever wasthemost frequenteventin our studyfollowed 
byheadache andrunning nose. Thefrequencies and ranking of the different types ofAEFIs were not 
always the samein previous campaigns. Feverwas the commonestsystemic symptomreportedfortwo 
out of three campaigns and the secondfor the last onewhileheadachewas the first symptomreported 
foroneout of three campaignsand thesecondin one out of three(23; 22; 21; 32; 30; 31).The type of 
AEFI, thetemporarysequenceof their occurrence after vaccination,and the course with a gradual 
decline over the eight weeks of surveillance suggest that a given proportion of thesesymptoms and 
signs was probably related tovaccination. 
Standardization of procedures to aggregate reported events in medically meaningful groupings is 
essential totrace AEFIsin vaccines clinical development and marketed phase, among different 
manufacturers, andto shareinformationbetween actors involvedinthesafety of vaccines. We 
aggregated reported AEFIs in SOCs following MedDRA(25; 24). To the best of our knowledge, no 
previous study has presented reported AEFIs following administration of the vaccine MenAfrivacTMin 
SOCs. Proportions of ‘Gastrointestinaldisorder’ and ‘Respiratory, thoracic and mediastinal disorders’ 
reported in age group1-4years were higher than in older age groups. Thiscan be explained by the 
higher background incidence of diarrhea and cough inyounger children. 
The incidence of AEFIs reported from theNorth Westregion was at leastthreetimes higher than in 
theAdamaoua. Similarly,the incidence rate was about 100 times higher in Batibo Health Districtthan 
that estimated in the Tignere health district. No difference in AEFI types as categorized by SOC was 
detected when comparing proportions of types of AEFIs in each region. The 
unequalspatialdistribution of reported AEFIshas already been observedin other countries ((33; 22; 
21). Information onthe geographic distribution ofreported AEFIis necessaryto monitorsurveillance 
activities.Areas with low reporting rate should be stimulatedto do better by adopting good practices. 
The low AEFI reporting rate in the Adamaouaregion can be explained by thelimited geographical 
accessibility ofhealth facilities and different health seeking behavior(28; 34; 35). Thistrend has also 
been observed for other health outcomes. For example, results of the 2011 national health 
demographic survey shows that only 46% of women delivered in a health facilityin theAdamaoua 
Regionwhile this percentage was93% intheNorthWest one (35). One of the possible responses to this 
low reporting rate could be the establishment of acommunity-based AEFIs surveillance which has 
been proven to improve AEFI reporting rate(36). 
The interpretation of the above findings should be taken with some caution since up to16% of 
reported AEFIs and 55% of serious ones could not be analyzeddue tolowcompleteness 
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orincoherentdata. The number of persons vaccinated was not detailed in days or weeks and could 
not allow to estimating AEFI incidence rate per week. 
CONCLUSION
Theincidence rates of overall and serious AEFIsreported from the vaccination campaign against 
meningococcalmeningitisAheld inCameroonin December2012 were higherthan 
inpreviouscampaigns, probablybecause of the intensified monitoring system put in place. 
Theincidencedeclined over the surveillance period and varied according to age group, health districts 
and regions. The distribution of theseAEFIsand review ofpreviousdataon MenAfrivacTMsafety 
supports the assumption that a given fractionof theseAEFIswas probably related to immunization. 
The present assessment did not detect any newserious AEFI and did not note any increase in serious 
AEFI rate compared to previous mass immunization campaign withMenAfrivacTM. This supports the 
large-scale use of this vaccine to prevent meningitis A epidemics and mortality in Africa. 
Observed age group differences in incidence and type of AEFI could be explained by different 
background incidence of diseases and different susceptibilities or reporting in these different age 
groups.
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Chapter 6: Vaccines safety; effect of supervision or SMS on 
reporting rates of adverse events following immunization (AEFIS) 
with meningitis vaccine (MenAfrivac™): a randomized controlled 
trial
Abstract
Authors: Jérôme ATEUDJIEU, Beat STOLL, Georges NGUEFACK-TSAGUE, Christophe TCHANGOU, 
Blaise GENTON
Background. To ensure vaccines safety, given the weaknesses of the national pharmacovigilance 
system in Cameroon, there is a need to identify effective interventions that can contribute to 
improving AEFIs reporting.
Objective.To assess the effect of: i) sending weekly SMS, or ii) weekly supervisory visits on AEFI 
reporting rate during a meningitis immunization campaign conducted in Cameroon in 2012 using the 
meningitis A conjugate vaccine (MenAfriVac™).
Methods. Health facilities that met the inclusion criteria were randomly assigned to receive: i) a 
weekly standardized SMS, ii) a weekly standardized supervisory visits or iii) no intervention. The 
primary outcome was the reported AEFI incidence rate from week 5-8 after the immunization 
campaign. An intention-to-treat approach was used to assess outcomes. All missing values were 
crosschecked and data were retrieved from the regional delegations by the study teams before data 
entry. The incidence rate of reported AEFIs was estimated per study group. The effect of 
interventions was compared between study groups by estimating the rate ratio (RR) and the 
attributable risk. The significance of the difference was estimated using the Z test, confidence 
intervals and p value. The Poisson regression model was used to estimate the effect of interventions 
on reported AEFI on incidence rates, after adjusting for potential confounders, namely the 
cumulative number of AEFIs reported from Week 1-4, the health region, the type of health facility 
and position of the health professionals acting as the AEFI focal points. Data were entered in epi info 
version 3.5.3 and analyzed using Stata version 10(Texas, 2009) and IBM SPSS 19. The level of 
confidence of our estimates was 95%. 
Results
A total of 348 (77.2%) of 451 health facility wereincluded, and 116 assigned to each of three groups. 
The incidence rate of reported AEFIs per 100 health facility per week was 20.0 (15.9-24.1) in the SMS 
group, 40.2 (34.4-46.0) in supervision group and 13.6 (10.1-16.9) in the control group. Supervision 
led to a significant increase of AEFI reporting rate compared to SMS [adjusted RR=2.1 (1.6-2.7; 
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p<0.001] and control [RR=2.8(2.1-3.7); p<0.001)] groups. The effect of SMS led to some increase in 
AEFI reporting rate compared to the control group, but the difference was not statistically significant 
[RR =1.4(0.8-1.6); p=0.07)].
Conclusion 
 Supervision was more effective than SMS or routine training in improving AEFI reporting rate. It 
should be part of any AEFI surveillance system. SMS could be useful in improving AEFI reporting 
rates but strategies need to be found to improve its effectiveness, and thus maximize its benefits. 
Registration number: PACTR201201000454298 
Key words: SMS, supervision, AEFI surveillance, immunization campaign, meningitis, Cameroon. 
BACKGROUND
The major goal of immunization safety surveillance is to detect and respond appropriately to 
Adverse Events Following Immunization (AEFIs) in order to reduce its potential negative impact on 
the success of immunization programmes (17).
An AEFI is medical incidence occurring after immunization and believed to be caused by 
immunization (2). Types, seriousness and frequency of AEFI depend on the product and the medical 
history of the vaccine recipient (3; 4). AEFIs are susceptible to cause minor or serious harm to 
individuals, as well as negatively affect to the national immunization program, including a reduction 
in the population’s use of the program (5). During vaccination campaigns, risk of AEFIs occurring is 
higher since a very large number of people are vaccinated at the same time and rumors can have 
damaging consequences on vaccine uptake (6; 7). 
In Cameroon, AEFI surveillance is an integral part of the EPI (8). It is part of the national 
pharmacovigilance system which is based in the Directorate of Pharmacy, Medicine and Laboratories 
(9). Weaknesses in this system include insufficient motivation and training of personnel at different 
levels; limited coordination and resources; and low AEFI and ADR (Adverse Drugs Reactions) 
reporting, investigation, completeness and timeliness rates. The system is implemented within 
routine EPI activities but is much more active and supported during immunization campaigns. For 
example, all immunization campaigns conducted in the last four years included AEFI surveillance (10; 
11). Reports from these activities highlighted the same weaknesses as the national 
pharmacovigilance activities as well as a positive effect of supervision on these parameters. For 
example, during a yellow fever immunization campaign that took place in 2009 in 62 health districts 
in Cameroon, 362 AEFIs were reported, including 53 serious cases. Ninety-two of the cases or 25% of 
all reported AEFIs were detected as a result of supervision conducted in only 20% of the target 
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health districts during the last week of AEFI surveillance. These included eight serious cases (28.8% 
of all serious AEFIs reported).
Supervision is the standard recommended intervention in Cameroon to ensure that AEFIs 
monitoring, reporting, and cases investigation take place (8). However, the efficiency of supervisionis 
limitedsince it requires a lot of resources in terms of personnel, coordination, funding and logistics 
to sustainably contribute to the monitoring of field activities (12; 13; 14). Short Messages Services 
(SMS) has been shown to improve health outcomes among patients in African countries by 
increasing health workers’ adherence to guidelines (15; 16; 17). It is thereforea potentially valuable 
tool to remind health professionals to identify and report AEFIs. The coverage of mobile phone 
networks in Cameroon was estimated in 2011 to be more than 90% (18). 
This paper describes research conducted in conjunction with meningitis A immunization campaign 
that took place from 3rd -16th December 2012 in two health regions in Cameroon (Adamaoua and 
North West) that are part of the African belt (19). The campaign used the new conjugate vaccine 
against group A Meningococcus (MenAfriVacTM) produced bySerum Institute of India. This vaccine 
has been shown to be efficacious and extremely safe (132; 133; 134; 135).
The aim of the study was to assess the effect on AEFI reporting, after the meningitis vaccination 
campaigns, of sending a weekly standardized SMS to health workers in charge of AEFI surveillance in 
health facilities or conducting standardized supervision of these personnel using skilled supervisors. 
We hypothesized that either of these interventions would result in higher AEFI reporting rates than 
the routine AEFI surveillance activities (i.e., “no intervention”). 
METHODS
Registration 
The study was approved by the Cameroon National Ethics Committee and registered in the Pan 
African Clinical Trial Registry (www.pactr.org) database with PACTR201201000454298 as the unique 
identification number. 
Study design. 
The study used an open randomized controlled design with three arms. All health facilities that were 
registered in health districts targeted in the 2012 meningitis A campaigns and that met the inclusion 
criteria were randomly assigned to receive: i) a weekly standardized SMS asking them to report all 
medical events occurring during the intervention period in persons immunized during the campaign, 
ii) a weekly standardized supervisory visit by trained health district focal points for AEFI detection 
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and reporting processes, or iii) no intervention besides routine training and sensitization of health 
facility teams during health districts coordination meetings (the control group). The primary 
outcome was the incidence of AEFIs per 100 health facilities per week reported to the Regional 
Delegation of Public Health. Informed consents of all health workers were obtained after the nature 
and possible consequences of the studies had been fully explained to them.
Participating health facilities
Inclusion criteria for health facilities in the study included the existence of at least one health 
professional appointed or accepting to be the health facility focal point for AEFIs during the 
meningitis A campaign surveillance period, their ownership of a mobile telephone and their 
commitment to be present during the study period. Non-functional health facilities, those not 
covered by at least one of national mobile telephone networks, those with AEFI focal point who 
expected to be absent for at least one week or during one of interventions were excluded from the 
study. 
The study targeted health facilities that were officially registered in all 27 health districts of the 
health regions of Adamaoua (8 health district) and North West (19 health districts). The official 
document mapping out Cameroon’s health facilities indicates that there were 468 health facilitiesin 
these two health regions in 2011, including 136 in the Adamaoua region, and 332 in the North West 
region (24). 
Interventions
Pre-intervention procedures 
Field activities conducted in all health districts before intervention are shown in Figure 4.
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Group 
assignment 
Training  Interventions 
Pre-campaign 
Figure 4: Flow diagram of field activities during the implementation of the study
Interventions
iv) SMS: Mobile phone numbers of AEFIs focal points in health facilities in the SMS groups were 
cross-checked by calling each owner. Messages to be sent were taped, crosschecked and 
saved onto a mobile telephone. Each week for four consecutive weeks, standardized SMS 
were sent to all AEFIs focal points in the SMS group at 8:00 a.m. on Monday in one language 
(French or English) and on Tuesday in the other language (the order was alternated from one 
week to the other) to all AEFIs focal points in SMS health facility group at 8:00 AM. The 
content of the messages was the same each week and included a reminder of the 
MenAfriVac™ AEFI surveillance period, case definition of an AEFI and a recommendation to 
actively detect and report all occurring AEFI on a daily basis. The ‘’delivery report’ ’function 
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of the mobile phone was used to verify if the message was received and opened.
v) Supervision: Each week, a nurse trained in supervision and AEFI surveillance visited on 
Monday or Tuesday each health facility to supervise the focal point on AEFI detection and 
reporting using a standardized grid. This grid included structured questions to check if the 
supervisee had included AEFI surveillance in his or her daily time table and if he/she knew 
the AEFI case definition, the AEFI surveillance period, how to detect and report a case and 
what to do with a serious AEFI case. Weaknesses were corrected by supervisors using 
standardized guidelines. The supervisory visits were verified by checking the stamps and 
signatures of the head of the health facility on supervisor’s mission orders. 
Control 
Health facilities in the control group received no additional AEFI-related interventions apart from 
what all health facilities normally receive during a vaccination campaign, namely pre-campaign 
training on AEFIs surveillance, passive AEFI monitoring during the campaign and 42 days after and 
monthly sensitization of health facility teams during health district coordination meetings. 
Outcomes 
The primary outcome was the incidence rate of reported AEFIs per 100 health facility per week 
during the intervention period, (Week 5-8 after immunization (31 December 2012 to 27 January 
2013). The numerator was the sum of reported AEFIs and the denominator was the number of 
health facilities multiplied by the number of weeks of the intervention. The secondary outcome was 
the reported incidence rate of serious AEFIs.
For each health facility, baseline information was collected on the health region, health district, 
category of health facility (e.g., integrated health center vs. other), and type and position of health 
professionals designated as the AEFIs focal point. In addition, the number of AEFIs reported before 
the interventions were implemented was collected at North West and Adamaoua Regional 
Delegations of Public health. 
Sample size 
The sample size calculation was based on the test of the null hypothesis that there is no difference 
between supervision or SMS on AEFI reporting rate compared to no intervention. The level of 
significance was set at 0.05 with 2-tailed test. The sample size was calculated using the WHO 
publication on Sample Size Determination in Health Studies (25). Assuming equal numbers of health 
facilities in each of the three groups, 150 health facilities or 50 per group were needed to give 80% 
power to detect a 5% increase in reported AEFI per health facility per week. To account for a 
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compliance rate of 80% and 20% drop-out rate, the sample size was increased to 300 health 
facilities. 
Randomization
 Health districtsthat had health facilities included in the study wereranked in alphabetic order from A 
to Z using the filter function of Excel 2010. The health facilities were also ranked in the same order 
per health district. All its key variables (health region, health district, type of health facility, type and 
position the focal point) except its name were hidden during the assignment process. The facilities 
were then randomly assigned to the SMS, supervision and control arms in blocks of three following a 
1:1:1allocation ratio. All combinations of blocks were listed and a number assigned to each 
combination. Numbers were generated from Table XXXIII of Fisher and Yates(26) as follow: an 
arbitrary starting point was chosen in the table and from that point; numbers were read row by row 
across pages. 
Statistical analysis
An intention-to-treat approach was used to assess outcomes. All missing values were crosschecked 
and data were retrieved from the regional delegations by the study teams before data entry. The 
incidence rate of reported AEFIs was estimated per study group. The effect of interventions was 
compared between study groups by estimating the rate ratio (RR) and the risk relationship. The 
significance of the difference was estimated using the Z test, confidence intervals and p value. The 
Poisson regression model was used to estimate the effect of interventions on reported AEFI on 
incidence rates, after adjusting for potential confounders, namely the cumulative number of AEFIs 
reported from Week 1-4, the health region, the type of health facility and position of the health 
professionals acting as the AEFI focal points. Data were entered in epi info version 3.5.3 and 
analyzed using Stata version 10(Texas, 2009) and IBM SPSS 19. The level of confidence of our 
estimates was 95%. 
RESULTS
Recruitment, participants’ flow and baseline data 
During the first half of December 2012, a total of 451out of 468 registeredhealth facilities (96.4%) in 
the two health regions were visited and asked to participate in the study. One hundred and three 
(22.8%) were excluded, including 39 (37.9%) in the Adamaoua and 64 (62.1%) in the North West 
health regions. Reasons for exclusion included absence of a cell phone networks (77 (74.8%), the 
health facility was non-functional (21 (20.4%)) and other reasons (5(4.9%)). A total of 348 (77.2%) 
health facilities were included, and 116 were assigned to each of three groups. Three health 
facilities, including two in the SMS group and one in the supervision group, withdrew before the 
interventions started because the health professionals selected to receive intervention were not 
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available and could not be replaced. Figure 5 shows the enrolment and assignment processes of 
health facilities in the flow in the study. Table 12 shows the characteristics of health facilities and 
health professionals by study groups.
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Assessed for eligibility (n=451)
Excluded (n=103) 
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(n=100)- Declinedtoparticipate(n=3)
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Withdrew before interventions ( =2)
 supervision arm (n=116)
Received allocated 
interventions (n=115)
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(n=116)
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114)
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116)
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115)
Analyzed(n=114) Analyzed (n=115) Analyzed 
(n=116)
Screening
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Follow up
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Figure 5: Flow diagram of the study
Table XII: Characteristics of health facilities and Health professionals included in the study, by 
intervention group
Characteristics Total SMS group Supervision 
group 
Control group 
n % n % n % n % P value 
Health facilities 
By region
North West region 263 76.2 87 33.1 87 33.1 89 33.8 0.980
Adamaoua Region 82 23.8 27 32.9 28 34.2 27 32.9 0.980
By type of health facility:
Integrated Health Centers 231 66.9 79 34.2 74 32.0 78 33.8 0.870
Other health facilities 114 33.1 35 30.7 41 36.0 38 33.3 0.700
Health personnel 
By position within the 
facility:
Head of integrated health 
centers
216 62.6 79 36.6 72 33.3 65 30.1 0.360
Other position in the health 
facility
129 37.4 35 27.2 43 33.3 51 39.5 0.110
By types of health 
professional
Nurses 325 94.2 107 33.0 110 33.8 108 33.2 0.970
Other 20 05.8 7 35.0 5 25.0 8 40.0 0.590
Outcomes and risks estimation
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Figure 6 presents the evolution of the number of AEFI reported before intervention (weeks 1-4) and 
during intervention period (weeks 5-8) in the different groups. During the intervention period, 339 
AEFIs were reported from participating health facilities, including 91 from the SMS group, 185 from 
the supervision group, and 63 from the control group. The number of health facility -weeks observed 
was 456 in the SMS group, 460 in the supervision group and 464 in the control group. The incidence 
rates of reported AEFI were 20.0 (15.8-24.1) AEFIs per 100 health facilities per week in the SMS arm, 
40.2 (34.4-46.0) in the supervision arm and 13.6 (10.1-16.9) in the control arm. 
Figure 6: Number of AEFI reported before the interventions (Week 1-4) and during the 
intervention period (Weeks 5-8) in the different intervention groups
The crude incidence rate of AEFI reporting rates of the interventions groups compared to the control 
groups is shown in Table 13 The incidence rates of reported AEFIs in SMS and supervision groups 
were superior to that of the control group. The AEFI reporting rate in the supervision group was also 
superior to that in the SMS group. The attributable risk of AEFIs reporting per 100 health facilities 
per week in the SMS and supervision groups compared to the control group were 6.38 (0.1-12.8) and 
26.6 (9.9-33.3) respectively. This rate in the supervision group compared to the SMS group was 20.3 
(13.3-27.3). 
Table 14 presents the incidence rates of the interventions groups compared to the control group 
after adjustment for the cumulative number of AEFI reported during the four weeks prior to the 
intervention, the health region, type of health facility, and type and position of thehealth 
professionals serving as AEFI focal points. The incidence rate of reported AEFIs in SMS group was 
superior but not statistically different to that of the control group [RR =1.4 (0.8-1.6; p=0.070)], while 
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the incidence rate of reported AEFIs in supervision group remained significantly superior to that of 
the SMS [adjusted RR=2.1 (1.6-2.7; p<0.001] and control group [RR=2.8 (2.1-3.7; p<0.001)]. 
A total of 17 serious AEFIs were reported during the intervention period including seven from the 
SMS, 9 from the supervision and 1 from the control groups. This resulted in incidence rate of 1.53 
serious AEFIs per 100 health facility per week in the SMS group, 1.95 in the supervision group and 
O.22 in the control group. 
Table XIII: Crude incidence (RR) rate comparing AEFI reporting rates of the interventions groups to 
that of the control group using simple Poisson regression.
Group RR 95% IC RR P value 
SMS 1.5 (1.1-2.0) 0.022
Supervision 2.9 (2.2-3.9) <0.001
Control 1
Table XIV: Adjusted rate ratios comparing outcomes in interventions groups to that of the control 
group using multiple Poisson regression
Group allocation RR 95% IC RR P value 
Groups 
SMS 1.4 (0.8-1.6) 0.07
Supervision 2.8 [2.1-3.7) <0.001
Control 1
Regions
Adamawa 0.3 (0.2-04) <0.001
North west 1
Type of health facility
Integrated health centers 1.6 (1.2-2.2) <0.001
District and other hospitals 3.1 (2.0-4.9) <0.001
Private health center 1
Type of health professional receiving the 
intervention
Nurses 3.7 (1.0-9.8) 0.024
Lab technician 4.9 (1.3-18.0) 0.017
Other health professionals 1
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Health professionals’ position
Head of health facility 2.0 (1.5-2.7) <0.001
Not heading the health facility 1
Cumulative number of AEFI
reported prior to the interventions 
(Weeks 1-4 following immunization) 
1.04 (1.04-1.06)  <0.001
AEFI: Adverse Events Following Immunization.DISCUSSION 
Results of this study show thatweekly supervision of health professionals in charge of AEFI 
surveillance in health facilities significantly improved the reporting rate compared to sending 
standardized SMS to these health professionals or to the standard practices. Sending SMS to remind 
health professionals about AEFI surveillance improved AEFIs reporting rates compared to the control 
group but not significantly. This studyis unique in that it is the first measure the effects of 
supervision and SMS on AEFI reporting rate. 
A benefit of supervision in increasing AEFIs reporting rate, timeliness and completeness of AEFI 
reporting have already been observed during previous AEFI surveillance conducted following 
immunization campaigns in Cameroon (10). These results are also in line with other studies of 
different health activities that showed benefits of supervision in improving job satisfaction, 
knowledge, skills and performances of health workers (13; 27; 28). Unlike recommended in 
someguidelines, weekly supervision was done bynurses who were not superior to those they were 
supervising in terms of rank or qualifications (i.e., peers), but who were well trained andhadtimeand 
resourcesto do their job properly. The supervision was interactive, and included responses to 
knowledge gaps. Thus, it was expected to not only remind supervisees about AEFI reporting, but also 
to improve their ability to detect and report AEFIs. This approach has been shown from previous 
studies to be more efficient and less costly, as well as to have a broader reachthan routine 
supervision typically conducted on a less frequent basis by higher level health personnel who are not 
necessary trained to supervise the tasks in question (27; 29; 30)
The fact that the effect of weekly SMS on AEFI reporting rates was not statistically different to that 
of control group does not mean that SMS has no effect on AEFIs reporting. Our study, in fact, 
showed that the rates of reporting serious AEFIs were quite similar in the supervision and SMS 
groups and both much higher than in the control group. A beneficial effect of SMS on AEFI reporting 
has been shown in Cambodia, but the study lacked acontrol group(31). Studies conducted in various 
settings of the efficacy of SMS in improving health care delivery have had varying results (32; 16; 33). 
Optimal circumstances and strategies for the use of SMS to remind health workers about AEFIs 
reporting are still to be clearly defined (34; 35). The SMS in this study were designedto remind 
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thetargeted health workers about the AEFIcase definition, the surveillance period, and the reporting 
process, with the expectation thatall suspected AEFI cases would be reported and all serious cases 
investigated. The fact thatthere wasno interactionbetween thesender and receiversof the SMS could 
have contributed to reduce the effectiveness ofSMScompared to face-to-facesupervision.Receiving, 
reading and understanding aSMSmay not necessarilylead to the expected response, especially if the 
personreceiving itis notconstrained ormotivatedto do so. Previous studies have reported high 
response rate among health professionals after having incentives added to the SMS reminder 
although this optionraises the question ofsustainability when implemented in a routine program(36; 
37). 
 Supervision is already recognized as a useful intervention when successfully integrated into health 
activities and programs (40; 41; 42; 27; 39). However, its effects are often below expectations 
because of the limitations of the health system to conduct it properly (41). The concern is not only to 
determine how to set up supervision to make it more efficient, but also to identify the most efficient 
interventions that can replace or be associated with it in order to improve the monitoring of health 
interventions. One of the interesting findings of the present study is that it has shown that nurses 
can supervise other nurses on AEFI reporting at the district level. Further studies could be designed 
to evaluate the effectiveness and efficiency of different supervision strategies on AEFI reporting at 
all levels of the health system. It could also be useful to compare the efficiency of using nurses as 
peer supervisors to that of more typical supervision strategies using supervisorsofhigher level 
professionalsand to determine the circumstances in which SMS can help to improve AEFI 
monitoring. Other interventions and modes of delivery could be tested such as sending letters, using 
incentives, sensitizing vaccinated populations using mobile phones or the internet, and training that 
have been shown to improve health program performance (43; 44; 45; 46; 47). 
Though health facilities participating in this study were sampled from only two of the ten health 
regions of Cameroon, the characteristics and distribution of these health facilities and the health 
professionals working in them were similar to those in Cameroon as a whole (38; 31). This suggests 
that our findings are applicable to the country as a whole and to other health systems with similar 
characteristics (39).
This study has some limitations. Data on some important variables that could have been included in 
the regression model to adjust for confounding were not collected. These included number of 
newpatient visits made during theintervention periodperhealth facility and the immunization 
coverage rate of the population served by the health facility. The number of patient visits was not 
collected because patient registration forms and procedures are not standardized in the 
participating health facilities. The immunization coverage rate was not collected since immunization 
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activities were conducted both in health facilities and communities and reported per health area, 
but not per health facility. In addition, the completion rate of AEFI reporting formswas very lowand 
some important variables such as, the date of consultation, were missing on the forms. These 
weaknesses didnot allow us to estimate some important parameters of AEFI surveillancesuch as 
promptness and identification of all serious AEFIs.
CONCLUSION
The results of this study show that weekly supervision of health professionals in charge of AEFI 
surveillance in health facilities significantly improved the AEFI reporting rate compared to sending 
standardized SMS to these health professionals or to routine AEFI-related activities. Sending weekly 
standardized SMS to remind health professionals on AEFI surveillance improved only slightly overall 
AEFI reporting rate. This study also demonstrates that it is feasible to effectively supervise health 
staff at the district level using nurses. Ifthis approach can be confirmed to be sustainable over time, 
it should be scaled up to improve themonitoring health programmes and activities in Cameroon and 
in other countries with similar health system. 
We recommend that when planning AEFI surveillance during vaccination campaigns, supervision 
should be included as an intrinsic part of the program. Strategies need to be identified to improve 
the effectiveness of supervision to maximize its benefits. More work needs to be done to determine 
whether regular SMS can contribute to improvements in the rate of AEFI reporting, and if so, how 
and in which circumstances the impact can best be achieved. Other interventions such as alternating 
SMS and supervision or sending SMS to the vaccinated persons or their parents should also be 
tested. 
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ABSTRACT
Background
Adverse event following immunization (AEFI) surveillanceis requiredin allphases of vaccines 
development. However, the rigor inthe implementation of thisrequirement differs fromclinical 
trialphases to mass immunizationcampaigns.
Objective
To compare the AEFIs incidence between clinical trials and vaccinationcampaignswith the new 
conjugate meningitisAvaccine (MenAfrivac™).
Methods
This is a systematic review ofstudieson MenAfrivac™ safety in clinical trialsandvaccination 
campaigns. The search was conducted for the period 2001-2014 in English in the meningitis vaccine 
project website and by consulting the list of publications in Medline (PubMed) and Embase (Ovid) 
using following terms: ‘’meningococcal meningitis A’’AND ‘’conjugate vaccine’’ AND ‘’safety’’ in 
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Medline; ‘’meningococcus’’ OR ‘’Neisseria meningitidis group A’’ AND ‘’conjugate vaccine’’ AND 
‘’safety’’ in Ovid. AEFIs incidence rates (IR) were estimated and compared between MenAfrivac™ 
clinical trials and immunization campaigns and incidence rate difference (IRd) is reported. 
Results 
Seven studies were included from 6 publications including 4 clinical trials and 3 immunization 
campaigns. The overall AEFI IR was 4.6 (4.5-4.7) per 100’000 doses administered per week. In clinical 
trials studies, the IR per 100’000 doses administered per week of overall, local, and systemic AEFIs 
were 10’047, 11’499, and 17’248respectively. Pains at the injection site had the highest IR among 
local reactions and diarrhea the highest IR of systematic reactions. In immunization campaigns, the 
IR per 100’000 doses administered per week, for overall, local, and systemic AEFIs were 4.0, 0.59, 
and 3.12 respectively. The highest IR among local reactions was pain at injection site and among 
systematic reactions fever. None of 10 serious AEFIs reported during clinical trials was related to the 
vaccine. Of 41 serious AEFIs reported during immunization campaigns, 5 were probably related to 
vaccine. IR of AEFIs were thus higher in clinical trials than in immunization campaigns studies, the 
difference (IRd) for overall AEFIs being of 10043 (95% CI 10042-10044) per 100’000 doses per week, 
for local of 11’498 (11’498-11’498), for systemic of 17’245 (17’245-17’245)] and for serious AEFIs of 
1.55 (1.54-1.56). The AEFI IR decreased by more than 99.9% for overall, local, systemic and serious 
AEFIs from clinical trials to immunization campaigns. 
Conclusion
As expected, the incidence of AEFIs after MenAfrivac™ vaccination was lowerin mass immunization 
campaigns than in clinical trials studies. The magnitude of the difference was huge. Although the 
objective of pharmacovigilance is not to identify all minor AEFIs, sustainable strategies mustbe 
developed to improve the detection and reporting of significant AEFI during mass immunization 
campaigns in order to have an accurate picture of vaccine safety, and potentially identify program 
errors.
Key words: MenAfrivac™ safety, AEFI surveillance, clinical trials, immunization campaign, 
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BACKGROUND
In clinical trials, themonitoring of vaccines anddrugs safety is mandatory and harmonized. Assessing 
vaccine’s safety is the mainobjectiveofphase Iclinical trials but the number ofparticipantsislimited 
and does not allow the detection of rareadverse events(1). The gradual increase insample size of 
participants inphases 2, 3, and 4clinicaltrials remains suboptimal todetect rare adverse events 
following immunization ‘AEFIs)compared tothe marketed phase of vaccines(2; 3).
Post-licensure surveillance of AEFIs is expected to improve vaccines safety by detecting and 
investigating new, rare, program errors or delayed-onset AEFI not detected in pre-licensure clinical 
trials or when new vaccine schedules are adopted (4; 5). Itprovides useful informationto anticipate 
orrespond to public concernsabout the safety ofvaccinesand thus contributes inincreasingthe 
adherence of thepublicto vaccination(5; 6). Thecurrently publishedstudies indicate thatAEFIs 
surveillanceisbelow expectationsdue toweaknessessuch as lowdetection, reporting and investigation 
rates(7; 8; 9; 10). Comparing thegeographical distribution ofAEFIsurveillance dataprovided 
usefulinformation to monitorvaccinessafety and to map some weaknesses of AEFIs surveillance 
systems(11). The comparisonof the incidence and type ofAEFI collected during vaccine clinical 
development phases and post-marketing surveillance, and an estimation of the magnitude of the 
difference could be useful to evaluate the amount of rare AEs that are missed in clinical trials as well 
as the amount of AEs that are not considered sufficiently important to be reported by either 
vaccinees themselves or health professionals during immunization campaigns or routine 
implementation. 
ThePSA-TT vaccine (MenAfrivac™) was developedtorespond to MeningococcalmeningitisA outbreaks 
ragingin more than 21African countries(12). Clinical trials phases of the vaccine showed the vaccine 
to be safe and effective (13; 14; 15). It was thus licensedin India in 2009 andpre-qualified by WHOa 
year later(12). Fromits introduction inBurkina Fasoin 2010 to 2012,10African countries have 
beentargetedby vaccination campaigns,immunizingmore than 100million individuals(12). AEFI 
surveillance has been part of these campaigns and its results have been published in three countries 
(16; 17; 18; 19). 
With an aim to contribute in providing useful information for better planning and monitoring of 
AEFIs surveillance activities during MenAfrivac™campaigns, this study has as objective to 
comparethe incidence and distribution of AEFIsreported during clinical trial phases to that reported 
during immunization campaigns.
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Our hypotheses were that i) AEFIs incidence gradually decreasefrom Phase 1toPhases 2, 3, 4 and 
vaccinationcampaign due to the factthat AEFIs surveillance progressively loses its place as central 
question over thesephases; ii) fromphase 1tophases 4 clinical trials and to vaccination campaigns, 
thenumber of peoplevaccinatedgradually increases, the immunized population is thus diversifiedand 
allows the detection of rareseriousAEFI and eventually AEFI that only occur in specific populations; 
moreover conditions ofstorage and useof the vaccine areless likely to be complied to,predisposing 
toa potentialincrease ofAEFIs incidence.
METHODS
2.1. Study design 
A review was conducted to identify all published studies reporting adverse events following 
MenAfrivac™ administration during clinical trials and immunization campaigns. The incidence rate 
(IR) of overall, local, systemic, serious and types of reported AEFIs were estimated and compared 
between clinical trials and immunization campaigns studies using the incidence rate difference (IRd). 
2.2. Study settings 
Studies conducted in all sites were included. 
2.3. Study population 
Were included studies reporting adverse events following immunization with meningococcal group A 
conjugate vaccine from male and female subjects aging 1 to 35 years old. These were age 
groupstargeted byclinical trials andvaccination campaigns MenAfrivac™.
2.4. Literature search
Theliterature searchwasbased onthreestrategies that included:
i) Safety information from the web site of meningitis vaccine project
The web site of the meningitis vaccine(20) project was accessed to collect reports and references of 
studies reporting AEFIs in clinical trials and in mass immunization with MenAfrivac™. For full text of 
reports missing in this website, the search was conducted by its title or first author’s name in 
Medline (PubMed) and Embase (Ovid). 
ii) Systematic search in Medline (PubMed) and Embase (Ovid)
A systematic literature search was conducted in PubMed and Ovid using the following combinations: 
‘’meningococcal meningitis A’’AND ‘’conjugatevaccine’’AND ‘’safety’’ in Medline; and 
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‘’meningococcus’’ OR “Neisseria meningitidis group A’’ AND ‘’conjugate vaccine’’ AND ‘’safety’’ in 
Ovid. 
iii) Consultation of article references 
An additional manual search was conducted in reference lists of eligible articles. The search was 
conducted from February 15th 2015 to March 17th 2015.
2.5. Eligibility criteria 
Were eligible, phase 1, 2, 3 clinical trials studies, and mass immunization campaigns studies 
reporting AEFIs after exposure to MenAfrivac™. 
2.6. Selection criteria
Were included: studies in English language and reports published from 2001 (when the MenAfrivac™ 
was launched) to 2014, reporting AEFIs following exposure to the vaccine MENAFRIVAC™.Study 
participants exposed to MAfrivac™ were included. The definition of AEFI was based on the WHO 
definitions (21; 1). 
Were excluded: i) unpublished reports, reports not published in peer reviewed scientific journal, ii) 
publications reporting AEFIs following concomitant exposure of participants to MenAfrivac™and 
anothervaccine or drugs; iii) duplicates (case where more than one publication reports AEFIs from 
the samepopulation overthe same period); iv) publications with AEFIs reported in preclinical phase 
of MenAfrivac™development; v) publicationsforwhich the full textwas not available;and vi) 
abstractsofconferences. Were also excluded participants to whom the vaccine administered was not 
done following manufacturer dose, administration or storage procedures.
The selection was conducted by two reviewers independently, following a two-step process: first, 
assessing the title and abstract, and second, assessing the full text, using the selection criteria. All 
disagreements were resolved by consulting full text of articles. 
2.7. Data extraction 
A data extraction grid used fora previous study was adapted (11). Data were extracted by one 
reviewer and compiled in an excel table. A second reviewer cross-checked one by one all extracted 
data comparing data in the excel table to filled data extraction forms and full texts of articles. In case 
of discrepancies, corrections were made from the full text article. The following characteristics were 
extracted from each article: characteristics of the study (study design, year of publication, study 
country, health care setting, type of resource available, source of the report, name of the first 
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author), characteristic of the study population (size, age group, inclusion criteria, exclusion criteria, 
number of pregnancies exposed), phase of the vaccine development (phase 1, 2, 3, 4 clinical trials, 
mass immunization campaign, routine EPI), characteristics of the vaccination (antigen, dose, 
administration procedure, other vaccine or drugs concomitantly administered, first or second dose), 
characteristics of the AEFI surveillance system (case definition of AEFI, case definition of serious 
AEFI, type of surveillance (active, passive stimulated or not), surveillance duration, type of AEFI 
investigated), characteristics of reported AEFIs [total number, number of serious, number of local 
reaction, number of systemic reaction, number of AEFIs per age group, number of AEFI per type, 
number of clusters AEFIs, number and type of AEFIs among pregnant women, number of serious 
AEFIs investigated, number of vaccine product-related reaction, number of vaccine quality defect-
related reaction, number of immunization error-related reaction (formerly “program error”), 
number of immunization anxiety-related reaction, number of coincidental events]. 
2.8. Outcomes
The primary outcome was the incidence rate difference (IRd) of overall AEFIs between clinical trials 
and mass campaign studies. Secondary outcomes were the IRd comparing local, systemic, serious 
and types of AEFIs between clinical trials and mass campaign studies. 
2.9. Quality assessment 
To assess the methodological quality of studies, we assessed procedures of participants’ selection, 
the adopted cases definition of AEFIs, procedures of AEFIs detection, reporting and investigation. 
The quality assessment was independently conducted by two reviewers. Any discrepancy was 
resolved through discussions. 
2.10. Data analysis 
IR per 100’000 doses administered per week of overall, local, systemic, and serious and types of 
AEFIs in clinical trials and mass campaigns were estimated. The numerator of the incidence rate was 
the sum of cases of AEFI reported and its denominator, the sum of persons exposed to the vaccine 
multiplied by the duration of follow up. AEFI IRs in clinical trials were compared to that of post 
registration phases by estimating the IRd and its 95% confidence interval. Data were entered in 
Microsoft excel 2010 analyzed using the same software and Stata version 10 (Texas, 2009).
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RESULTS
3.1. Study selection 
The search identified 123 titles including 53 (43.1%) from the Meningitis Vaccine Project (MVP) web 
site, 58 (47.2%) from Medline, 10 (8.1%) from Ovid and 2 (1.6%) from references of articles. After 
duplicates were removed, 108 titles and abstracts were screened of which 9 full texts were selected 
and 6 included in the study. Three were excluded because presenting too aggregated summaries on 
reported AEFIs (22; 23; 24). Figure 7 presents details of selection process. In total 11’476’276 doses 
of MenAfrivacTM including 1’190 in clinical trials and 11’475’086 in immunization campaigns were 
reported in included articles to have been administered following manufacturer recommendations. 
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Figure 7: Flow diagram of the study selection
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 3.2. Study characteristics 
Characteristics of included articles are presented in Table 15. Three articlesreported clinicaltrialsand 
included4studies (13; 15; 14); two articles reported two studies on AEFI surveillance during 
immunization campaign and one article reported a phase 4 field trial study assessing MenAfrivacTM 
safety when delivered in a controlled temperature chain(18; 17; 25). Characteristics of AEFIs 
surveillance are presented in Table 16. 
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Table XV: Characteristics of included studies
Author: year of Publication; 
country (reference)
Study 
period 
Region/ or site Phase of 
vaccine 
development 
Age 
group 
(years )
Number of 
persons exposed 
to PsA-TT
Dose of 
PsA-TT 
administered 
Number of 
administere
d doses per 
person
Vaccine 
manufacturer 
Kshirsagar, 2007, India (13) 2005-2006 King Edward Memorial (KEM) Hospital, 
Mumbai; (2) Nizam’s Institute of Medical 
Sciences, Hyderabad; (3) BYL Nair 
Charitable Hospital, Mumbai.
phase I 
clinical trial 
18-35 24 0.5 ml One Serum Institute of 
India Ltd.
Sow; 2011; Gambia, Mali 
Senegal (14), (A)
2006-2009 Centre pour le Développement des Vaccins 
in Bamako, Mali ; Medical Research 
Council ; Laboratories in Basse, Gambia 
and ; Institut de Recherche pour le 
Développement in Niakhar, Senegal
Phase II 
clinical trial 
1-2 201 exposed to 
primary dose and 
192 exposed to 
booster
0.5 ml primary 
vaccination 
and booster
Serum Institute of 
India Ltd.
Sow; 2011; Gambia, Mali 
Senegal (14), (B)
2007-2009 Centre pour le Développement des Vaccins 
in Bamako, Mali ; Medical Research 
Council ; Laboratories in Basse, Gambia 
and ; Institut de Recherche pour le 
Développement in Niakhar, Senegal
Phase II-III 
clinical trial
2-29 604 exposed 
including 203 in 
age group 2-10, 
202 in age group 
11-17, and 199 in 
age group 18-29
0.5 ml One Serum Institute of 
India Ltd.
Hirve ; 2012; India (15) 2007-2008 Shirdi Sai Baba Hospital, Pune, India Phase II-III 
clinical trial
2-10 169 0.5 ml One Serum Institute of 
India Ltd.
Maman; 2012; Niger (17) September–
November 
2010.
Niger, the district of Filingué, Post 
registration 
(immunizatio
n campaign) 
1-29 356’532 0.5 ml One Serum Institute of 
India Ltd.
Ouandaogo, 2012, Burkina 
Faso (18)
September 
–December 
2010
The whole country Post 
registration 
(immunizatio
n campaign)
1-29 11’117’555 0.5 ml One Serum Institute of 
India Ltd.
Steffen; 2014 ; Benin (25) November 
–December 
2012
Four villages in Banikoara (vaccine use in 
CTC1 ) and four villages in Kandi (vaccine in 
recommended ranged of cold chain)
Post 
registration 
(Phase IV)
1-29 1000 in CTC and 
999 in the non-
CTC group
0.5 ml One Serum Institute of 
India Ltd.
1: CTC: controlled temperature chain (exposing vaccine at temperatures of up to 40°C for up to four days)
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Table XVI: Characteristics of AEFI surveillance
Study Did case 
definition of 
minor AEFI 
comply with 
WHO guidelines 
Did case 
definition of 
serious AEFI 
comply with 
WHO guidelines
Was the case 
detection 
active(a) or 
passive (b) or 
both (c)
Did allvaccinated persons 
have the same 
probability to be 
detected in case of AEFI
Was the 
reporting 
procedure 
standardized 
Were 
serious 
AEFI 
investig
ated 
Who was in 
charge of 
serious AEFI 
investigation
What was the total duration in 
days of AEFI surveillance for each 
person exposed
Kshirsagar 
2007 (13)
Minor AEFI not 
defined 
Serious AEFI not 
defined
c Yes Yes Yes Research team Observed for 3h after vaccination, 
actively followed up for 7 days for 
solicited reaction, 28 for 
unsolicited reactions, 365 for 
serious AEFIs
Sow 2011(A) 
(14)
Minor AEFI not 
defined
serious AEFI not 
defined
c Yes Not described Yes Research team 28 days including 30mn 
observation and 4 days active 
monitoring, 280 days for serious 
AEFI and 450 for serious after 
booster
Sow 2011(B) 
(14)
Minor AEFI not 
defined
serious AEFI not 
defined
c Yes Not described Yes Research team 28 days including 30mn 
observation and 4 days active 
monitoring, 280 days for serious 
Hirve: 2012 
(15)
Minor AEFI not 
defined
serious AEFI not 
defined
c Yes Yes Yes Research team 28 AEFI surveillance including 30 
mn observation after vaccination, 
4 days active monitoring, 365 
surveillance of serious AEFIs 
Maman 2012 
(17)
Yes Yes b No (case detection was 
health facility-based and 
access to health facility 
was not presume to be 
equal for all people 
vaccinated)
Yes Yes The Committee 
in charge 
42 days 
Ouandaogo 
2012 (18)
Yes yes c No (case detection was 
health-facility based and 
access to health facility 
was not presume to be 
equal for all people 
vaccinated)
yes Yes The Committee 
in charge
42 days 
Steffen 2014 
(25)
Minor AEFI not 
defined
serious AEFI not 
defined
c Yes Not described Yes The Committee 
in charge
5 days 
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 3.3 Incidence of AEFI in clinical trials and in immunization campaign studies
IR of overall AEFI in clinical trials and immunization campaigns studies are presented in table 17 The 
AEFI IRs of clinical trials, mass immunization campaigns and overall were 10’047.0 (10’046-10’048), 
4.0(3.9-4.1) and 4.6 (4.5-4.7) AEFIs per 100’000 doses administered per week respectively 
Table XVII: Incidence rate (IR) of overall reported studies in clinical and campaign studies
Study Vaccine 
developmen
t phase 
Number 
of AEFIs 
reported 
Number of 
doses 
administered 
Duration of 
AEFIS 
surveillance 
in days 
Duration of 
surveillance 
in persons 
week 
IR (number of 
AEFI per 
100’000 
doses 
administered 
per week)
Kshirsaga
r 2007 
(13)
phase 
1clinical trial 
27 24 7 24 112’500.0
Sow 
2011(A) 
(14)
Phase 2 
clinical trial 
179 393 28 1’572 11’387.0
Sow 
2011(B) 
(14)
Phase 2-
3clinical trial
110 604 28 2’416 4’553.0
Hirve: 
2012 (15)
Phase 2-3 
clinical trial
155 169 28 676 22 928.9
Total 
clinical 
trials 
471 1’190 4’688 10’047.0
Maman 
2012 (17)
Phase 2-3 
clinical trial
356 356’532 42 2’139’192 16.6
Ouandao
go 2012 
(18)
Post 
registration 
(immunizatio
n campaign) 
2’008 11’466’950 42 68’801’700 2.9
Steffen 
2014 (25)
Post 
registration 
(immunizatio
n campaign)
439 999 5 713,57 61’522.0
Total 
campaign 
studies 
Post 
registration 
(Phase 4)
2’803 11’824’481 7’0941’606 4.0
Overall 
clinical 
trials and 
campaign 
studies 
3’274 11’825’671 70’946’294 4.6
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AEFI incidence in clinical trials 
For the majorityof clinical trials, details on the type of AEFIs were available onlyforthe 4-7 days 
ofsurveillance;thus,onlythis period wastaken into accountin estimating IR of AEs per type and 
characteristics (local or systemic) in clinical trials studies. Table 18 presents AEFI IR in clinical trials 
studies. The IR per 100’000 doses administered per week, of local and systemic AEFIs were 11’499, 
and 17’248 respectively. The highest IR among local AEFIs was for pain at injection site and among 
systematic AEFIs was diarrhea. 
 AEFI incidence in mass vaccination campaigns 
The IRs of AEFIs reported during studies in vaccination campaigns are presented in table 19 In 
immunization campaigns, the IR per 100’000 doses administered per week of local and systemic 
AEFIs were 0.59, and 3.12 respectively. The highest IR among local reactions was for pain at injection 
site and among systematic for fever. 
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Table XVIII: Incidence of different types of AEFIs following MenafrivacTM in clinical trials studies
AEFI type Kshirsagar 2007 (13) Sow 2011(A) (14) Sow 2011(B) (14) Hirve: 2012 (15) Overall 
Number 
of cases 
reported
Time of 
surveillance 
in person 
week (1)
Number 
of cases 
reported
(
 (2)
Time of 
surveillance in 
person week
Number 
of cases 
reported 
(2)
Time of 
surveillance in 
person week
Number 
of cases 
reported 
(2)
Time of 
surveillance 
in person 
week
Number 
of cases 
reported
Time of 
surveillance 
in person 
week
Incidence rate (number 
of AEFI per 100’000 
doses administered per 
week) 
Pain at the 
injection site 
18 24 17 225 30 345 Ag1 676 65 1’270 5’119
Induration/ 
redness 
injection site
3 24 17 225 7 345 Ag1 676 27 1’270 2’126
Swelling 
injection site 
2 24 0 225 0 345 Ag 676 2 1’270 158
Abcess 0 24 0 225 0 345 0 676 0 1’270 0.00
Total local 
reaction
23 24 34 225 37 345 52 676 146 1’270 11’499
Fever 0 24 13 225 18 345 0 676 31 1’270 2’441
Headache 1 24 0 225 45 345 0 676 46 1’270 3623
convulsion 0 24 0 225 0 345 0 676 0 1’270 0.00
Cough 0 24 0 225 0 345 0 676 0 1’270 0.00
Running nose 0 0 225 0 345 0 676 0 1’270 0.00
Vomiting 0 24 7 225 8 345 0 676  15 1’270 1’181
Diarrhea 0 24 40 225 6 345 0 676 46 1’270 3’623
Loss of 
appetite
0 24 14 225 1 345 0 676 15 1’270 1’181
Irritability 0 24 4 225 0 345 0 676 5 1’270 315
Asthenia 1 24 0 225 10 345 0 676 11 1’270  866
Pruritus 0 24 0 225 0 345 0 676 0 1’270 0.00
Sudden 
fainting 
0 24 0 225 0 345 0 676 0 1’270 0.00
Myalgia 0 24 0 225 3 345 0 676 3 1’270 236
Arthralgia 1 24 0 225 2 345 0 676 3 1’270 236
Other 1 24 0 225 0 345 0 676 1 1’270 79
Total 
systemic 
4 24 78 225 93 345 44 676 219 1’270 17’248
(1): Considered duration of surveillance; 7 days; (2): Considered duration of surveillance: 4 days; Ag: aggregated 
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Table XIX: Incidence of types of AEFIs following MenafrivacTM in vaccination campaign studies after 42 days surveillance
AEFI type Maman 2012 (17) Ouandaogo 2012 (18) Steffen: 2014 (25) Overall 
Number of 
cases reported
Time of surveillance 
in person week
Number 
of cases 
reported
Time of 
surveillance in 
person week
Number of 
cases 
reported
Time of 
surveillance in 
person week
Number of 
cases 
reported
Time of 
surveillance in 
person week
Incidence rate (number of AEFI 
per 100’000 doses 
administered per person week) 
Pain at the 
injection site 
4 2’139’192 Ag 68’801’700 155 714 159 70’946’886 0.22
Induration 
injection site
0 2’139’192 Ag 68’801’700 11 714 11 70’946’886 0.00
Swelling 
injection site 
0 2’139’192 0 68’801’700 0 714 0 70’946’886 0.03
Abscess 7 2’139’192 16 68’801’700 2 714 25 70’946’886 0.04
Total local 
reaction
11 2’139’192 243 68’801’700 168 714 421 70’946’886 0.59
Fever 53 2’139’192 779 68’801’700 103 714 935 70’946’886 1.32
Headache 25 2’139’192 310 68’801’700 33 714 368 70’946’886 0.52
Convulsion 22 2’139’192 17 68’801’700 0 714 39 70’946’886 0.06
Cough 3 2’139’192 0 68’801’700 0 714 0 70’946’886 0.00
Running nose 0 2’139’192 0 68’801’700 0 714 0 70’946’886 0.00
Gastrointesti
nal disorders 
(Ag)
37 265 68’801’700 35 714 320 70’946’886 0.45
2’139’192 68’801’700 714 70’946’886
2’139’192 68’801’700 714 70’946’886
Irritability 0 2’139’192 0 68’801’700 4 714 4 70’946’886 0.01
Asthenia 0 2’139’192 15 68’801’700 32 714 47 70’946’886 0.07
Pruritus 22 2’139’192 84 68’801’700 21 714 127 70’946’886 0.18
Dizziness or 
Sudden 
fainting 
3 2’139’192 120 68’801’700 0 714 123 70’946’886 0.18
Myalgia 3 2’139’192 96 68’801’700 27 714 126 70’946’886 0.18
Arthralgia 1 2’139’192 24 68’801’700 7 714 34 70’946’886 0.05
Other 4 2’139’192 55 68’801’700 0 714 59 70’946’886 0.08
Total 
systemic 
170 2’139’192 1765 68’801’700 281 5994 2216 70’946’886 3.12
1 Ag: aggregated 
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Serious AEFI in clinical trials and vaccination campaign studies 
  A total 51 serious AEFI were reported including 10 (1.56 serious AEFIs per 100’000 doses 
administered per week) in clinical trials studies and 41 (0.08 serious AEFIs per 100’000 doses 
administered per week) during mass vaccination campaigns studies. Types and etiologies of serious 
AEFIs in clinical trials and vaccination campaigns are presented in tables 20 and 21 respectively. 
Types of AEFI reported during clinical trials studies differed to that reported during vaccination 
campaign studies. None of serious AEFIs reported during clinical trials was related to the vaccine 
after causality assessment of all reported cases. Causality assessment was conducted for 40 out 41 
reported serious AEFIs in vaccination campaign studies and 5 were probably related to vaccine 
(12.5%) and 5 (10%) were not classified because of lack of information
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Table XX: Type and etiology of serious MenAfrivacTM AEFIs in clinical trials
Study duration of 
surveillance in 
days
number of 
vaccine doses 
administered 
Type of AEFI 
(symptom/sign or 
preferred term 
Delay between 
vaccination and 
AEFI occurrence 
SOC where indicated Causality 
relationship with 
the vaccine 
Number of 
cases 
Outcome 
Kshirsagar 2007 
(13)
365 (one year) 24 toothache 6days Not indicated Unrelated 1 Not indicated 
Sow 2011(A) 
primary 
vaccination (36)
730 (Two years) 201 Note indicated Not indicated Infections an 
infestations 
Unrelated 1 Recovered 
Acute Gastroenteritis Not indicated Infections an 
infestations
Unrelated 1 Death 
Protein energy 
malnutrition
Not indicated Metabolism and 
nutritional disorder 
Unrelated 1 Death 
Sow 2011(A) 
Booster (14)
730 (Two years) 192 Injury Not indicated Injury, poisoning and 
procedural 
complications
Unrelated 1 Death
Note indicates Note indicated Vascular disorders 1 Recovered 
Sow 2011(B) (14) 365 604 Injury and poisoning 
and procedural 
complications
Unrelated 1 Recovered
Pregnancy, 
puerperium and 
perinatal conditions 
Unrelated 1 Recovered
Hirve 2012 (15) 365 169 Acute lymphoblastic 
leukemia
23 days Not indicated 1 Remission (under 
chemotherapy)
Chronic tonsillitis More than 28 days 
after 
Not indicated Unrelated 1 Recovered
Total 10
SOC: System Organ Class
(A) : study A in the article; (B) study B in the article
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Table XXI: Types and causes of serious AEFIs following administration of MenAfrivacTM in vaccination campaigns
Study duration of 
surveillance in 
days
number of 
vaccine doses 
administered 
Type of AEFI 
(symptom/sign or 
diagnosis)
Delay between 
vaccination and 
AEFI 
occurrence 
SOC Causality 
relationship 
with the vaccine 
Number of 
cases 
Outcome 
Maman 2012 
(17)
42 356’532 Severe malaria (13 were 
reported to have fever, 8 
convulsions, 8 
gastrointestinal disorders 
and all 14 have positive 
malaria smear) 
Not indicated Severe 
malaria 
None was 
related 
(Coincidence )
14 Not clear 
Vomiting, diarrhea, 
hypothermia (35°C), 
convulsion and coma
1 day Not indicated Not conducted 1 The child 
died two 
hours 
after 
admission 
Allergic reaction: rash 
and intense pruritus, 
bronchospasm and 
erythematous and 
edematous plaques on 
all the body
30 minutes Not indicated Probably related 
to the vaccine
1 Not clear 
Ouandaogo 
2012 (18)
42 11’466’950 Exanthematous 
pustulosis 
Not indicated Not indicated Probably related 
to the vaccine
1  Not clear 
Angioedema Not indicated Not indicated Probably related 
to the vaccine
1  Not clear 
Bronchospasm Not indicated Not indicated Probably related 
to the vaccine
1  Not clear 
Vomiting Not indicated Not indicated Probably related 
to the vaccine
1  Not clear 
Not indicated Not indicated Not indicated Coincidence 17 Not clear 
Not indicated Not indicated Not indicated unclassified 4 Not clear 
Steffen: 2014 
(25)
5 999 0 
total 41
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3.4. Comparing AEFI incidence rate in clinical trials and vaccination campaign studies
The IRds of local, systemic, types and serious AEFI are presented in table 22 IR of AEFIs were higher 
in clinical trials than in immunization campaigns studies, the difference (IRd) for overall AEFIs being 
of 10043 (95% CI 10042-10044) per 100’000 doses per week, for local of 11’498 (11’498-11’498), for 
systemic of 17’245 (17’245-17’245)] and for serious AEFIs of 1.55 (1.54-1.56). The IRd of some types 
of AEFI is not presented due to the fact that some studies opted to aggregate data on some type of 
AEFIs. Headache had the highest IRd [3’622 (3’622-3’623)]. The IR decreased by more than 99.9% for 
overall, local and systemic AEFIs and by 99.5% for serious from clinical trials to immunization 
campaigns 
Table XXII: Incidence rate difference of types of AEFI between clinical trials and immunization campaigns
Type of AEFI Incidence rate in 
clinical trial 
(number of AEFI 
per 100’000 doses 
administered per 
person week)
Incidence rate 
immunization 
campaigns (number 
of AEFI per 100’000 
doses administered 
per week)
Incidence rate 
difference 
(number of AEFI 
per 100’000 doses 
administered per 
week)
[95% Conf. Interval]
Pain at the 
injection site 
5’119.26 0.22 Ag
Induration 
:redness 
injection site
2'126.46 0.00 Ag
Swelling 
injection site 
157.52 0.02 Ag
Abscess 0.00 0.04 -0.04 [-0.05—0.03]
Total local 
reaction
11498.65 0.59 11498.06 [11’498.02-11’498.09]
Fever 2441.49 1.32 2440.18 [2’440.17-2’440.19] 
Headache 3622,86 0.52 3622.35 [3’622.34-3’622.36]
convulsion 0.00 0.06 -0.06 [-0.08--0.04]
Cough 0.00 0.00 0.00
Running nose 0.00 0.00 0.00
Vomiting 1’181.37
0.44 5’985.16 [5’985.09-5’985.23]
Diarrhea 4’252.93
Loss of appetite 1’417.64
Gastro 
intestinal 
disorder
5’986.60
Irritability 315.30 0.01 315,02 [314.94-315,10]
Asthenia 866.34 0.07 866,27 [866.25-866.29]
Pruritus 0.00 0.17 -0.17 [-0.19- -0.13]
Dizziness or 
Sudden fainting 
0.00 0.18 -0.18 [-0.20- -0.14]
Myalgia 236.27 0.18 236,10 [236.09-236.10]
Arthralgia 236.27 0.05 236,23 [236.22-236.24]
Other 78.76 0.08 78,66 [78.65-78.67]
Total systemic 17’247.97 3.12 17’244.85 [17’244.80-17’244.90]
Ag: At least one study had the number of aggregated in a syndrome
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  3.5. Risk of bias within studies
Table 23 presents the assessment of risk of bias in included studies. Information on participants’ 
selection in clinical trial studies was not sufficiently detailed for a thorough assessment of the risk of 
selection bias in these studies. Cases definitions of minor and serious AEFIs were not presented for 
all clinical trials and limited the assessment of detection bias. The duration and detection procedures 
of AEFI surveillance and of serious AEFI surveillance were not the same in all included studies and 
predisposed to an increase risk of detection bias across studies. There was also a risk of detection 
bias in studies conducted in immunization campaigns as all vaccinated populations did not have the 
same geographic access to AEFI surveillance. In some of the included studies, AEFI were only 
presented in syndrome or in systemic organ class without prior presentation of symptom or sign. 
This predisposed to an increased risk of reporting bias in and across studies. Available information 
was limited to rule out the risk-attribution bias for 6 out of 7 included studies as nothing was 
mentioned on how each study participants were followed up till the end of the surveillance period. 
The causality assessment of serious AEFIs was not clearly described in clinical trials studies while it 
was conducted by a multidisciplinary committee in campaign studies. This could increase the risk of 
bias across studies regarding classification of serious AEFIs.
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Table XXIII: Risks of bias for included studies
Study  Is there a risk of selection 
bias? 
Is there a risk of 
detection bias?
Is there attrition 
bias? 
Is there a risk of reporting 
bias?
Is there a risk of bias in 
assessing the etiology of 
serious AEFI
Kshirsagar 2007 
(13)
Unclear1 No4 Unclear6 Unclear8 Unclear9
Sow 2011(1) 
(14) (A)
Unclear1 No4 Unclear6 Unclear8 Unclear9
Sow 2011(2) 
(14) (B) 
Unclear1 No4 Unclear6 Unclear8 Unclear9
Hirve: 2012 (15) Unclear1 No4 Unclear6 Unclear8 Unclear9
Maman 2012 
(17)
No2 Yes5 Unclear6 Unclear8 Unclear9
Ouandaogo 
2012 (18)
Yes2 Yes5 Unclear6 Unclear8 Unclear9
Steffen 2014 
(25)
Yes3 No5 No7 Unclear8 Unclear9
Across studies Yes10 Yes10 Yes10 Yes10 Yes10
1: procedure of participants selection and enrolment not detailed; 2 : all eligible people in covered health districts were targeted by the vaccination 
campaign and AEFI surveillance; 3: study villages were selected by the Benin Ministry of Health; 4: the detection and reporting processed of AEFI were 
standardized; 5: Access to AEFI surveillance expected to differed among persons vaccinated; 6: the number of participants followed up till the end of 
surveillance period was not indicated; 7: all participant were followed up till the end of the five days surveillance period; 8: information about the 
supervision or the monitoring of reporting are not presented . 9: Processes of serious AEFI causality assessment were not presented; 10: the selection and 
follow up of participants, the AEFIs detection, reporting and investigation process differed from one study to 
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DISCUSSION
To the best of our knowledge this is the first systematic review comparing incidence rates of AEFIs 
between clinical trials phases and immunization campaigns with MenafrivacTM, but also with any 
other vaccines. It gives an insight on the magnitude of difference in incidence rates of overall, local, 
systemic, serious and types of AEFI when assessed in the rather controlled setting of clinical trials, 
especially in Phase 1 and 2, and just pragmatic during mass immunization campaigns. As expected, 
the incidence of AEFI was much higher in clinical trials than in mass campaign studies with a 
decrease of more than 99% for all AEFIs from different phases of clinical trials to immunization 
campaigns. None of the serious AEFIs reported in clinical trials studies was related to the vaccine 
while 5 out of 40 serious AEFIs investigated in immunization campaign studies were probably related 
to the vaccine. 
Since the objectives of clinical trials are completely different than those of mass immunization 
campaigns, the first one being primarily to assess the safety and reactogenicity of a new product, the 
second one being to protect a whole population from a disease, it is not expected to have equivalent 
IR of AEFIs. However, since the safety of a vaccine cannot be ascertained by clinical trials only due to 
the small sample size that hinders detection of rare significant AEFIs, it is highly desirable that a good 
surveillance system is put in place when a new product is distributed at large scale. Our observation 
of new serious probably vaccine-related AEFIs in mass immunization campaigns shows that there is a 
necessity to have a monitoring of safety in place during such enterprise, and that it can work. What 
this review does not show is the number of such events that were missed during campaigns. There 
are certainly many since the IR of serious AEFI was more than 99% lower in mass campaigns than in 
clinical trials. This observation is worrying. 
There are several reasons that can explain the magnitude of this difference. They can be categorized 
into two groups, namely one related to methodological differences and the second to the 
surveillance system in place. For the first one, the duration of observation may have played a role. 
Indeed, the surveillance period in clinical trials was shorter than in mass campaigns. This leads to a 
higher overall IR since AEFIs are mainly observed in the first or second week post vaccination. The 
numerator is therefore much higher. Diversity in vaccine safety monitoring procedures, surveillance 
periods as well as AEFI reporting and analysis have been identified to contribute in reducing accurate 
scientific information on vaccine safety (26). To maximize scientific progress on immunization safety, 
standardization of AEFI surveillance period in clinical trials and mass campaigns after registration is 
essential. The second reason for this big IRd is linked to the poor performance of the surveillance 
system in place during mass campaign to capture AEFIs. There are many challenges that have been 
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largely described in previous studies (27). Under-detection and under-reporting of AEFIs in mass 
campaigns are well known and intrinsic to an activity that is not focused on safety assessment. In 
clinical trials, the detection, reporting and investigation of AEFIs are part of the TOR of a well-trained 
monitored, supervised and audited research team. On the other hand, in mass vaccination 
campaigns, there is limited number of health personnel trained to supervise AEFI surveillance, 
detect, report and investigate cases of AEFI. From our experience in Cameroon, one focal point per 
health district is designated and trained for AEFI surveillance supervision and one focal point per 
health facility is designated and trained for the detection, reporting and investigation of cases of 
AEFIs. One person only to supervise surveillance in the whole district and one only in a big hospital is 
clearly not sufficient. Indeed, in a hospital where many serious cases are treated, and in different 
wards, at different times of the day and night, it is difficult to detect those that can be the result of 
an SAE. The consultation registers are not standardized and do not allow the detection of cases of 
AEFI after the consultation. They do not include variables on vaccination history. Thus, cases of AEFIs 
consulted in the absence of focal point have very little chance of being detected. Also, for lack of 
resources, the training of supervisors and focal points is often made in cascade and is integrated into 
the training of other campaign activities. The duration is often very short and decreases drastically 
when applied from central to operational level. Similarly competence of trainers decreases since one 
trainee cannot deliver better training than that received in a shorter time. Improvements can 
however be made such as by i) revising the patient registration system to include at least one 
variable for active case detection, ii) ensuring that all health workers receive initial or continuing 
training enabling them to implement the minimum AEFIs monitoring activities at the operational 
level, iii) sensitizing head of health facilities to include in TOR of all health personnel involved in care, 
the detection and reporting of AEFI, and this being even more important in hospitals, iv) to use 
efficient interventions such as continuous supervision and even SMS messages to remind health staff 
of their surveillance duty (24)). 
The poor performance of AEFI surveillance in mass campaign is worrying in terms of safety of 
vaccines because i) it misses local AEFIs such as abscesses for example that may be a key indicator of 
program error such as compliance with vaccine storage, transportation and administration 
procedures, ii) it misses severe local AEFIs which are preventable and are likely to draw the attention 
of the public and spread rumors and refusals for vaccination, iii) it misses serious AEFIs and 
compromises causality assessment and possibilities to appropriately respond to. 
To understand whether such differences of AEFIs reporting between clinical trials and mass 
vaccination were inherent to MenAfrivacTM or were common to all vaccines, we made a rough 
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estimate of the magnitude of the difference in IR of AEFIs between clinical trials and post 
registration immunization using the new pneumococcal conjugate vaccine 13. For 5308 doses of the 
vaccine administered during clinical trials, 5004 AEFIs were reported, including 1803 local and 3201 
systemic  (28; 29; 30; 31). While in post registration, 871 vaccine doses were administered and 550 
AEFIs were reported including 236 local and 314 systemic  (32). IRd per 100 000 doses per week 
between clinical trials and post registration vaccination were 19’089, 5'423, 13'666 and for overall, 
local, and systemic AEFIs reported respectively. Thus AEFI incidence decreased from clinical trials to 
post registration vaccination studies by 52%, 37%, and 53% for overall, local, and systemic AEFI 
respectively. This relatively low difference can be explained by the fact that in the post registration 
study, AEFI monitoring was more rigorous, which increased the chance of detecting AEFIs than 
during studies conducted during the vaccination campaigns with MenAfrivacTM. Also vaccinees were 
closely monitored for AEFIs by telephone throughout the monitoring period. Lastly, the vaccinated 
population was made up of people of older age in a European country.
Conclusion
This systematic review highlights the magnitude of the difference between IR of AEFI as evaluated in 
the controlled setting of clinical trials and more pragmatic approach of mass vaccination campaigns. 
IR of AEFIs was more than 99% lower in vaccinations campaigns than in clinical trials, including for 
the reporting of serious ones. Since the objectives might not be the same, safety and reactogenicity 
being the most important outcome in clinical trials, and detection of rare severe and serious events 
in mass campaign, there is no expectation of IR to be equivalent in the two settings. However, there 
is definitely room for improvement of the surveillance system in mass campaign and post 
registration implementation, including for example standardization of hospital registries with 
information on vaccination status, better case detection in hospitals to allow better investigation of 
causality, sufficient number of trainees and dedicated health staff in health facilities and hospitals, 
and adequate supervision, even with new technologies such as SMS reminders. 
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Chapter 8: General Discussion, Conclusion andRecommandations
8.1. General discussion
The main goal of this thesis is to identify sustainable interventions that can contribute to improvethe 
performancesof pharmacovigilance during mass immunization campaign with MenAfrivacTM in 
Cameroon. To this end, three studies were conducted and results are presented in Chapters 5, 6 and 
7. This chapter discusses main findings and presents general thesis recommendations on practical 
application and potential further studies based on the main study findings. 
8.1.1: Improving AEFI reporting rates of immunization campaign 
Chapters 5 and7of this thesisshowthatunderreporting ofAEFIsis a major obstacleto theupdate 
ofvaccinesafetyinformation and for the appropriate response to AEFIs in immunization campaigns. 
Chapter 6shows thatsupervisionof health staffor reminding them using SMS improvethe reporting 
rateofAEFIs. Taking into account these results when planning and implementingroutine or 
massimmunization have been recommended to improve AEFI reporting rate and to define 
apharmacovigilance system. Given thenecessary resources,thesustainableimprovement of 
pharmacovigilance includingvaccine pharmacovigilancealso depends on otherinitiativesand actions 
at different levels such as global level, health care system, pharmaceutical industry, scientific 
communityand on otherparameters that canaffect the qualityofinformationdescribing vaccine safety 
profile.
Since 1961, WHO has taken initiatives to enhance drug safety; and to support public health 
programs for the effective assessment of the risk-benefit profile of medicines.Vaccine safety isa 
priority targetfor thisactivity since 1999 through the establishment of the Global Advisory 
Committee on Vaccine Safety (GACVS) (183). A number of actions have been conducted in these 
perspectives focusing on strengtheningthe capacities of countriesinsetting up an efficient 
pharmacovigilance systems and boosting the international and national collaboration on drug and 
vaccine safety. Examples of these actions included setting up the Program for International Drug 
Monitoring, to collect reports of suspected adverse drug reactions to be incorporated into the WHO 
database and analyze; developing and sharing guidelines on drug and vaccine pharmacovigilance 
and developing training programs (190). This resulted in substantial progresses in some countries 
although improvement is still required as recent published reports revealed a rather slow progress in 
somecountries in the developmentandimplementationof vaccine pharmacovigilance system (33). 
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The number of countries collaborating with the WHO Program for International Drug Monitoring has 
substantially increased in recent years (81).In some countries there is willingness of decision 
makersto put in place basic structuresof the pharmacovigilance system (34).In general, in LMIC, the 
minimum resources, infrastructure,regulations, and guidelines to implement the pharmacovigilance 
activities are still lacking, limiting the capacity of generating the required information to assess the 
risk-benefit ratio of marketed vaccine (25, 32). To the best of our knowledge, no publication has 
focused on the reason for the poorimplementation of the WHO initiativein LMIC. From our 
experience in Cameroon, this can be explained by low coverage of staff needed to implement the 
initiative. Training programs that are offered in this context invite only a small proportion of people 
involved in AEFIs monitoring. These people often do not have the resources to organize training 
sessions and share their knowledge with their colleagues and other stakeholders. Guidelines 
developed by WHO are hardly solicited since those who should do so, are not trained on AEFIs 
surveillance and are not aware of it utility. Efforts to improve regulations usually target only the 
health staff while drafting documents and approving these documents often involve other people 
from other backgrounds and other sectors. Most health program managers are still unaware of the 
importance of pharmacovigilance. For example, one study showed that even when resources for 
pharmacovigilance are made available by Global Fund, only 27% of proposals included it in the 
request for funding (191). Improvementsmight be possiblein pharmacovigilance in general,if training 
on vaccine pharmacovigilance is included inbasic training of health personnel; if headof EPIand 
otherhealth programsusingdrugsare trained inpharmacovigilance, ifactions to improve 
regulationinvolve all key stakeholders,ifresources areallocatedto train a sufficient number 
ofhealthpersonnel at alllevels of the health system in pharmacovigilanceand if theminimum 
infrastructure, equipment, resources provided and guidelines are developed and made available.
Guidelines forthe creationand functioning ofa pharmacovigilance centerdo not definethe roles of 
governmentin the process (192).No other document, to the best of our knowledge does 
it.Declaration of Alma-Ata precises that Governments have a responsibility for the health of their 
people which can be fulfilled only by the provision of adequate health and social measures (193). It 
can be deduced that the Government has the responsibility to setup a functional pharmacovigilance 
system in each country. It should therefore be the responsibility of the government to creating and 
assigning objectives of pharmacovigilance centers, developing regulations and guidelines, allocating 
resources and infrastructure, appointing staff and evaluating the results of activities. Published 
studies indicate that in several countries, especially in LMIC, these initial steps are still not taken and 
no study to the best of our knowledge has attempted to describe the reasons (25, 32).In Cameroon, 
a Presidential Decree organizing the Ministry of Public Health creates the pharmacovigilance service 
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and assigns specific missions (79). The assigned tasks are matched to provide information necessary 
for the assessment of risks and benefits of medicines and vaccines. These tasks are almost not 
performed but no assessment has been done to explore the reasons. From our experience, the 
plausible explanations would includeinsufficient resources since to date no budget is planned for the 
implementation of pharmacovigilance activities. Ignorance also characterizes those responsible of 
health programs that involve drug use because no head of health programs including the EPI 
managersincludes pharmacovigilancein the yearly budget of their activities. Inadequate qualification 
and background of persons appointed to manage pharmacovigilance service is one of constraints 
because since this service exists, only nurses are appointed to operate. They usually lack necessary 
leadership, bravery and expertise to interact with health programs, health regions, health facilities, 
their hierarchy and international organizations; the lack of decentralization of pharmacovigilance 
units in the health regions and health programs; dependence on donors for fundingleading to 
unsustainability of activities. Improvement would be possible by appointing head of 
pharmacovigilance services sufficiently qualified and motivated persons to plan, mobilize local and 
external resources, stimulate the participation of key stakeholders, implement and assess key 
activities; creating pharmacovigilance units in all health programs, health regions, health districts 
and hospitals; allocating minimum local resources and equipment including computers and software 
for data management; and putting in  place an AEFIs data management and analysis system. 
The role of the pharmaceutical industry in investigating drugs and vaccine safety during clinical trials 
is well described (3). In Cameroon as in other countries, this role is not described for registered and 
marketed vaccines and drugs. The WHO Guidelines for setting up and running a pharmacovigilance 
center limit their role to receiving from pharmacovigilance services or the national regulatory 
authority reported cases of AE and AEFI occurring after exposure to drugs or vaccines produced by 
the concerned pharmaceutical company. This is reasonable as extending their role to support 
pharmacovigilance promotion or activities could directly or indirectly put pharmacovigilance centers 
in conflicts of interest in the assessing drugs risk benefit ratio.Their contribution couldbe beneficial 
in using reported AEFI or AE to generate and share information on drugs and vaccines safety profile 
especially in countries with poor pharmacovigilance system, to regularly update drugs and vaccine 
information sheets, and to identify, support or conduct research projects in order to clarify AEFI and 
immunization causal relationship which is imprecise after AEFI investigation. 
Given therelatively highcost of supervisionand the relativelylowefficacy ofSMSon improvingAEFIs 
reporting rates, it is necessary to explored new horizonsinorder to identify strategies that can be 
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used for sustainable improvement of AEFIs reporting rate. In Cameroon, the standardized EPI 
guidelines recommend supervision as the standard available intervention to ensure that tasks 
planned for each activity are performed following procedures as instructed (80).Supervision is 
known to be expensive and usually requires high expertise. Theseconstraints limitthe 
expectedcontribution ofsupervisionin improvinghealthinterventions outcomes. Chapter 6 of this 
thesis shows strategies to improve its efficiency. Other strategies could be tested to reduce it the 
cost. For example the assignment and training of AEFIs supervisors in health facilities or assignment 
of area supervisors to cover a given number of health facilities not distant from each other. Thus, 
bringing supervisors closer to supervisees could make it less expensive because the distance costs 
will be reduced. The integration of activities to be supervised could also reduce the costs of 
supervision as integration is known to increase the efficiency of health interventions (195). For 
example, in routine EPI, the supervision of AEFIs surveillance could be integrated in the supervision 
of epidemiological surveillance of EPI preventable diseases such as measles, yellow fever, materno-
neonatal tetanus, and acute flaccid paralysis. The surveillance of these diseases is regularly funded. 
Supervision of AEFI surveillance activities may be included at no additional cost. The AEFI reporting 
could also be improved by combining SMSand supervision to remind and train health personnel on 
AEFI reporting. Future studiescould thus test whetheralternatingSMS withsupervisioncould 
improvethenotification rateofAEFIs at low cost. We could alsoevaluate the effectof stimulatingmore 
than one personperhealth facility using SMS, hopingthat at least one of them reacts and that it 
results inan increase in theAEFIs reporting rate.SendingSMSto the communityhas been shown to be 
effectivein improvingthe detection ofAEFI(196).The combination ofsending SMSto 
thosevaccinatedandhealth personnelin chargeofAEFIsurveillance couldimprove SMS effectiveness in 
improving AEFI reporting rate and should beevaluatedin futurestudies.
Another way to improve the AEFIs detection and reporting rates is to target care seeking points.A 
study conducted in south Sudan showed that the therapeutic itinerary of patients with fever 
included the following:home, traditional healers, magicians, private formal and informal medicine 
vendors and health centers (198).In Cameroon, despite the differences in culture, these points are 
the same. A system could be set up where staffs working in these health care points alert health 
workers of the closest health facility in case an AEFI is detected. This system is being evaluated in 
Cameroon whether it can improve case detection and reporting of EPI preventable diseases under 
epidemiological surveillance. Traditional healers are involved in epidemiological surveillance and are 
asked to alert the health centers in case they detect a suspected case of any disease under 
surveillance. This is still under evaluation. On the same line, an unpublished study conducted in 
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Cameroon showed that the telephone warning system by ‘‘ beeb "(a short phone call not picked up) 
sent by parents of vaccinated children(followed by a phone call from the health center to collect 
additional needed data)significantly improved the AEFI reporting rates compared to the control 
group in which in case of AEFI, parents were advised to bring the child to hospital (199). Further 
studies could assess effects of intervention like ‘’beeb’’ or SMS sent from the community, pharmacy 
vendors or traditional healers, magician in case of an AEFI in improving AEFI reporting rate. 
Anyinterventions thathave been proven effectiveinimprovingvaccine 
pharmacovigilanceusingSMS,''beeb’’ or phone calls is not expected to encounterdifficultyduring 
implementation in Cameroon. Topromoteepidemiological surveillance, the WHO has made 
availabletoall health facilitiesfrom referral hospitalsto health centersmobile telephones and a 
network in whichmessages andcalls are free of charge.This greatlyreducesthe costsof 
interventionsand improves its feasibility.The concern ishow toensure sustainabilitywhenthe 
resources made availableby WHOwill be exhausted.
The integration of AEFI detection and reporting in a systemcollectingcommunity-basedinformation 
at a knownfrequencyis likely to improve AEFIsdetection and reportingrates at low cost. A study 
conducted inTanzania showedthat it is feasibleto integratethesurveillance of pregnant women 
exposuretodrugs within the health and demographic surveillance (HDS) platform (200). This 
integration included monthly visit of pregnant women and is presumed to improveAEFIreporting 
ratesas it increases number of health worker and patient contact. 
In Cameroon,AEandAEFIare notthe onlyhealth eventsunder surveillance(201). About thirty diseases 
are targeted by epidemiological surveillance. Incidences of cases reported for diseases under 
surveillance are by far lower than expected due to underreporting. The resultsof 
interventionstestedin Chapter 6could be appliedto improve thereportingof these diseases. This 
should be easy since the detection, reporting and investigation procedures in epidemiological 
surveillance and in vaccine pharmacovigilanceare the same.Given that both surveillances lack the 
human, material and financial resources for their activities, the integration of both 
activitiescouldimprove the results ofeach. For example further study could assess  the feasibility and 
cost-effectiveness of integrating activities of AEFI surveillance to that of epidemiological surveillance. 
8.1. 2 Improving other parameters of AEFI surveillance 
The reporting rate is not the only parameter that needs improvement to ensure proper monitoring 
of vaccine safety. Other parameters may need to be improved to insure that good information is 
used to describe vaccine safety profiles. These wouldinclude; case definition, types of AEFI detected, 
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reported and investigated, the causality assessment, completeness and timeliness of reporting 
forms, reporting and investigation of cases, developing and training on AEFI pharmacovigilance, 
andhow to evaluate the AEFI surveillance system.
 The AEFI case definition in vaccine clinical trials or in the post registration phases conditions the 
specificity and the sensitivity of the surveillance system which is the capacity of the system to detect 
the true suspected event in the population under observation (203). This definition is important in 
the monitoring system since its modification can change significantly, the number of detected 
cases.It is in this light that one must ask the question whether AEFIs case definitions used in clinical 
trials and post registration are sensitive enough, understood and used by the entire chain involved in 
monitoring? In WHO guidelines, aconstant evolution has been notedin the direction ofimprovingthe 
sensitivity ofAEFIs case definition. Thus, this definition evolved from “medical incident that takes 
place after an immunization and is believed to be caused by the immunization” (17) '' to “any 
untoward medical occurrence which follows immunization and which does not necessarily have a 
causal relationship with the usage of the vaccine (18) '' From field experience, the first definition is 
not sufficiently accurate as the expression “believed to be caused by the immunization” can leadto 
indecisionwhen a suspect case of AEFI is detected. The second definition which is the latest is easier 
to be taught, more easily understood and used by the health staff. But community volunteers and 
traditional healers who have important role in the therapeutic itinerary of patients in Cameroon and 
in many African countries are expected to have difficulties to understand and use the definition. 
Indeed, the expression 'medical occurrence' 'is not accurate and can have different interpretations. 
We believe that this definition should be assessed regularly and updated to ensure that it can be 
used by all categories of persons involved in AEFI surveillance.
Identification of adverse events following immunization in clinical trials, routine immunization or 
during immunization campaigns requires a clear and standardized definition of these events that is 
easy to be used by people involved. To date, the standardization of the definition of all events is still 
ongoing. Describing events using non standardized cases definitions can lead to non-homogeneous 
sensitivity and specificity of AEFIs surveillance system in clinical trials and post registration phases of 
vaccines development. The Brighton collaboration is an initiative that works to improve the 
assessment of the safety of vaccines with a very significant contribution in the development of 
formats and standardized case definition of signs and symptoms likely to occur after exposure to 
vaccines as well as the development of guidelines for data collection, analysis and presentation 
during AEFIs monitoring (77). The framework provides three levels of precision for each AEFI and 
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indicates the context of use for each. It is true that the sensitivity and specificity of definitions 
presented in three levels of accuracy was tested but in routine immunization and vaccination 
campaigns, these definitions are not easily applicable. For example fever definition seems very 
applicable regardless of the level of care but the required data collection details are more applicable 
in clinical trials setting where everything is standardized and closely monitored than in routine 
immunization (205).Details required to describe the thermometer used to assess the temperature 
are difficult to be provided since required details are not provided with thermometers sold in 
Cameroon. Providing practical training on required details per sign and symptom, ensuring the 
supervision of its implementation, and data collection would be very difficult during vaccination 
campaigns where the time allocated for training is short, the work load is very high for medical staff 
and some of cases are usually detected by non-medical staff. This may explain why in the results of 
the systematic review presented in Chapter 7The incidence of fever in clinical trials was different to 
that of immunization campaigns. 
Completeness of reporting forms, timeliness, proportion of appropriately investigated serious AEFIs 
cases, and the reliability of the data in the AEFI report form are other key parameters that need to 
be monitored (206). Where needed, these parameters could be improved concomitantly with the 
underreporting using the same strategies. 
In clinical trials, it is mandatory to collectquantify anddescribe eachAEFI (3). In themarketed phase, 
any AEFI that is of concern to the parents or to the health-care workers should be reported; 
particularly serious AEFIs, signals and events associated with a newly introduced vaccine, AEFIs that 
may have been caused by an immunization error-related reaction, significant events of unexplained 
cause occurring within 30 days after vaccination, and events causing significant parental or 
community concern (18).It is reasonable not to recommend reporting all types of AEFIs for marketed 
vaccines. If the monitoring system set up is sensitive enough, it would be unrealistic to report all 
cases. For example during the vaccination campaign against meningococcal meningitis A organized 
in Cameroon in 2012, over 2 million people were vaccinated, meaning about 70% of the population. 
National statistics indicate that fever for example can affect over 40% of the population in a month 
(207)In this population if 70% of people are vaccinated, it could happen that several cases of fever 
coinciding with the AEFI surveillance period occur. In this case, at least 100’000 case of fever would 
have occurred.It would not have been feasible to report all these cases which meet AEFI case 
definition. Given that it is required to monitor each event in order to assess the safety profile of the 
vaccine used, it would be more efficient to meet the earlier WHO recommendation in terms of type 
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of AEFI to be reported at marketed phase of vaccines and to develop a monitoring system that 
would randomly select either consultation days or patients consulting during the surveillance period 
of AEFIs to estimate the incidence of minor AEFI.
With the aim to update key information for vaccines safety Profile and the assessment of the risk 
benefit ratio, the detection, reporting, investigation and description of the causal relationship 
between serious AEFI and immunization is one of the main objectives of AEFIs monitoring (18). In 
Chapter 7 of this thesis, we noted that in clinical trials, the standardization procedures for detecting, 
reporting, investigation, analysis of causality is not always implemented. For post registration 
immunization, the reporting rate of serious AEFI was very low compared to clinical trials. Similarly, 
the low reporting rate, and poor qualityof investigation are common and this limits possibilities to 
draw conclusions regarding relatedness at the end of the causality analysis process. From field 
experience, the following explanations are plausible. Insufficiency of qualified and motivated human 
resources resulting in insufficient coverage ofhospitalized and monitoring period and the non-
detection of certain cases of AEFI due to ignorance of the case definition. Besides that,  financial 
resources are often inadequate to acquire sufficient amount of supplies for samples collection and 
to ensure transportation of samples from peripheral areas to the reference laboratory. Reported 
forms are received by the expert committee very late and incomplete to help improve the quality of 
investigation. The communication between the periphery and the committee is not sufficiently 
regular to support remote assistance in order to improve case investigation. Improvement is 
possible by increasing the duration of training and promoting the use of case studies. More frequent 
and closer supervision or sending SMS could also improve the AEFI detection and the quality of 
investigation. Minimum necessary consumables for sample collection should be supplied during 
campaigns. A rapid transfer of information using emails for example where possible could improve 
the timeliness and allow completion of the investigation when the patient is still hospitalized. In 
health facilities, anAEFIfocal pointshould be assignedin eachcare team.The guidelines onclinical trials 
shouldbe reviewed tostandardizeprocedures for detecting, reporting, and investigation ofAEFIsin 
clinical trials (3). On the same line, the improving the monitoring of clinical trials implementation by 
ethical committees or/and NRA can improve the compliance of research teams to clinical trials 
guidelines and to dear research protocols and SOP (standard operating procedures) 
Training onpharmacovigilance is one intervention that is expected to contribute in improving 
national capacities in implementing pharmacovigilance activities. Actually it is mainly promotedby 
WHO.It aims to strengthen and maintain capacity for national vaccine pharmacovigilance through 
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the delivery of E-learning courses, basic training, advanced trainings, the development of trainer 
resources, the creation of pool of national, regional and global experts in capacity building, and the 
respond to requests for training courses (190). The diversity of the program is expected to improve 
knowledge and practices of people involved in pharmacovigilance in countries. But the fact that 
several studies identified inadequate training as a major handicap in the ability of countries to 
conduct pharmacovigilance activities means that either the programs do not respond to training 
needs of those involved in pharmacovigilance, or the coverage of targeted population remainslow. 
As it was the case in strengthening capacities of African countries in research ethics evaluation, the 
program can be readjusted if needed by conducting a study to identify priorities in term of training 
objectives and targets (208). Periodic evaluation of these programs could also be useful to assess its 
efficiency (209). The discrepancy between the varieties of training opportunities and insufficient 
training could be justified by the fact that health personnel have limited access to these programs. 
Because very few perceive the need to be trained in pharmacovigilance since they are ignorant of 
the need. They are in this case unlikely to visit the indicated web site to download training resources 
or solicit training. Those who participate in training seminars are regularly those in charge of centers. 
At the end of these training, no resources are planned to replicate the training to other health 
personnel in health facilities, health program, health regions, and health districts and hospitals.It is 
thus unrealistic to think that the training offered by WHO can help to build the capacity of all health 
personnel in each developing country. Local training opportunities are offered during immunization 
campaigns and are too brief to impact a significant strengthening of pharmacovigilance among 
health personnel. A sustainable capacity building can be done by pleading to competent authorities 
for training on pharmacovigilance to be included in the basic training curricula of health personal. 
Ongoing training could have a better result through an increase in the promotion of E-learning in 
pharmacovigilance and decentralization of the planning and implementation of training seminar in 
country through calls for grant.
8.1.3 Safety profile of the vaccine MenAfrivacTM in mass immunization campaign
The safety profileof a marketedvaccine, as that of any drug,interestshealth personnel, managers of 
immunization programs,pharmaceutical industry,thepublic, thenationaldrugregulatory authority, 
non-governmental and international organizations involvedinvaccination; as it isan important 
parameterin the analysisof the risk-benefit ratio andin the decision-making process to develop and 
register vaccines, plan immunization activities, adherenceto vaccination program,and to plan 
responses to AEFIs occurring during immunization. 
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It is therefore essentialthat allefforts be made toensure that afterany mass immunization campaign 
orimmunization activity, information on vaccination coveragebe accompaniedwith the details,on 
vaccine safety. 
Results of the study presented in chapter 6 supported that MenAfrivacTM is safe. This conclusion 
islogical looking at comparisons of the distribution of overall, local, systemic, serious,and of types of 
AEFIs reported in the targeted campaign to that of previous campaigns(38). The conclusion would 
have been less reassuring about the safety of vaccines if it included details about shortcomings of 
the reporting process. As in this case a fifthofreportedAEFIwas notincluded in the analysisbecause of 
thepoorquality of reporting, the analysisof causalitywas notdone onmore than halfof seriousAEFIfor 
the same reasons, all newAEFIsdetectedwere notinvestigatedfor the same reasonsand that 
theincidence rate ofreportedAEFIwasthree times higherinone healthregion than the other and 
100times higher in one healthdistrictwith respectto another. This means that itisdifficult to 
makestatements aboutthe safety profileof avaccineused during avaccination campaign without the 
criteria validate the quality of the surveillance that generated the information. If not,a 
lowerstandard surveillancewillfail todetect someseriousAEFIsandwe believe that thenon-detectionof 
these AEFIsdoesnot confirm itsabsence. 
Almost all studies previously publishedon MenafrivacTM safety profile during mass campaigns 
support that the vaccine is safe but are more or less affected with the sameweaknesses. Inaddition, 
theaggregated anddetailed data onthe vaccine safety profile cover onlyone fifth and onetenth of100 
milliondosesadministeredbetween 2010 and 2012.These deficiencieson the qualityand 
completenessofAEFIdatacast doubtwhen reporting the vaccine safety and limit evidence baseline 
information when planning AEFIs surveillance. 
8.1.4: Magnitude and implications of AEFIs incidence rate difference between clinical trials and 
immunization campaigns
Mass campaigns increase the risk of AEFIs occurrence as campaigns often involves the use of less 
experienced personnel for vaccine administration, administering a large number of doses over a 
short periods of time, less chance to respect restrictions , contra-indication and drug interactions. 
The likelihood of detecting, reporting and investigation of AEFIs is higher in clinical trials since its 
research team members are better trained and monitored in their task and therefore likely to better 
comply with AEFI reporting and investigation procedures.
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In campaigns several parameters contribute to reduce the capacity of the health system to ensure 
proper AEFIs surveillance (38).The consequence is low AEFIs reporting rate. Ourconcern isthe 
magnitudeof the IRd between clinical trials and immunization campaigns that can beconsidered 
acceptable. Resolving this concern is expected to result in an indicator that can be used to judge the 
value of AEFI reporting rate in post licensure vaccination. To the best of our knowledge, this 
preoccupation has not yet been discussed in publications.
 It is utopian to expect zero AEFIs IRd between clinical trials and post registration vaccination. But, in 
order not to jeopardize the adhesion of the people to vaccination, each monitoring system should 
work to keep the AEFIs IRd close to zero for serious, local and those AEFIs that concern populations. 
With the hope that this performance would allow the detection and reporting of programme errors, 
rare AEFI and those related to group with particular physiological or pathological conditions.
A review conducted with results presented in chapter 7, found that AEFI IRd between clinical trials 
and mass campaigns with MenAfrivacMT regarding local, systemic and serious AEFI was very high 
with the IR decreasing by more than 99% from clinical trials to mass campaigns. Although the 
acceptable values ​​for these differences are not known, a simple judgment can deduce that they are 
large enough to cast doubt on the assertions about AEFIs safety profile based on AEFI surveillance 
data. 
We recommend that the Cameroon MOH should initiate the process leading to use the AEFI IRd 
between clinical trials and post registration vaccinations as an indicator of post registration AEFIs 
surveillance performance. This could be one of key indicator to be used in order to assess and 
monitor performances ofAEFissurveillance system putin placeduring immunizationcampaigns or 
supplementaryimmunization activities in Cameroun.
8.2 Conclusions
 The supervision of health facilities by trained health district nurses on AEFIs surveillance, 
significantly increases the reporting rate of AEFIs compared to routine AEFI surveillance 
practices during immunization campaigns
 The standardized SMS sent to remind health personnel on AEFIs surveillance increases, the 
AEFIs reporting rates compared to routine AEFI surveillance practices during immunization 
campaign 
 The supervision of health facilities by trained health district nurses on AEFI surveillance, 
increases AEFIs reporting rate better than sending the SMS, during immunization campaigns
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 Neither new nor increase incidence of  serious AEFIs relate to  MenAfrivacTM were 
detectedin the mass immunization campaign organized in Cameroon in December 2012  and 
thus supports that MenAfriVacTM vaccine is safe and should continue to be used in mass 
vaccination campaigns
 The incidence rate of AEFI reported in mass immunization campaign organized in Cameroon 
in December 2012 varied by health district and health region 
 The incidence rate of overall, local, and systemic, reported AEFIs during immunization 
campaigns was at least 99% lower than that reported in clinical trials and that of serious AEFI 
at 95% lower than that of clinical trials.
 The underreporting is one of the main barriers to the achievement of the objectives of AEFI 
surveillance during immunization campaign with MenAfrivacTM in Cameroon
8.3 Recommendations
What can be directly translated into public health policy?
 Key indicators should be defined for the monitoring of performances of vaccine 
pharmacovigilance during immunization campaigns. For example, using as indicator, the 
incidence rates differences of reported and investigated serious AEFIs between clinical trials 
and immunization campaigns
 During immunization campaigns, AEFI surveillance should anticipate the underreporting by 
stimulating AEFIs reporting using standardized SMS sent to health personnel and supervising 
health personnel using trained district nurses.
 Results of AEFI monitoring should be regularly published by the authorities in charge, to 
facilitate the compilation and analysis of data on vaccine safety,
 Monitoring and reporting procedure should be standardized between the phases of clinical 
trials, and post registration vaccination, countries, manufacturers and vaccination campaigns 
to facilitate comparison and monitoring of vaccine safety profile. The most sensitivecase 
definitionshould beused for allsuspected AEFIsandforseriousonesthe case definition should 
be standardized and adapted to the standard of care or laboratory as recommended by the 
Brighton collaboration. 
 The authorities in charge should design and validate respective training modules and 
objectives for supervisors and health workers involved in AEFIs monitoring.
 Head of health facilities should review the patients’ registration system to incorporate at 
least one variable on vaccination history to facilitate active detection of AEFIs cases.
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 The number of needed AEFIs supervisors in health districts and health facilities must be 
estimated and provided during immunization campaigns.
 The head of health facility have to include monitoring of AEFIs in the TOR of all health staff,
 Minimum needed supplies and resources for AEFI cases detection, reporting, investigation as 
well as samples collection and transportation, data analysis should be provided by 
authorities in charge.
 Coordination of activities between the EPI and the department of drugs, pharmacy and 
laboratory has to be improved 
 To improve it efficiencies, vaccine pharmacovigilance activities should be integrated in 
epidemiological surveillance activities and demographic health surveillance platforms where 
it exists. 

Research needed in the future
 Identify strategies to improve the effectiveness of SMS on AEFI reporting rate. For example 
testing the effect of stimulating the reporting of AEFI detection and reporting by sending 
concomitantly, SMS to health personnel in charge of AEFI surveillance and at community 
level to parents of children vaccinated
 Identify strategies to reduce the cost of supervision as intervention to improve AEFI 
reporting rate. For example, assessing the feasibility and cost effectiveness of using hospital 
and health area supervisors vs district supervisors on AEFI reporting rate 
 Identify key indicators for the monitoring of AEFIs surveillance during immunization 
campaign, Determining the acceptable incidence rate difference of reported and 
investigatedserious AEFIs between clinical trials phases, and immunization campaign and 
between clinical trials phase and routine immunization 
 Identify sustainable interventions to improve other parameters of AEFI reporting like the 
completeness of reporting forms and the AEFI investigation ratefor example, testing the use 
internet on improving the timeliness of serious AEFIs reporting and investigation 
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